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ABSTRACT 
 
Tobacco use, mainly in the form of cigarette smoking, is the leading cause of premature 
death in developed countries. Nicotine is the main addictive component of tobacco that motivates 
its continued use in spite of its harmful characteristics. Via binding to nicotinic acetylcholine 
receptors (nAChRs) nicotine affects several neurotransmitter systems in the brain. Activation of 
midbrain dopamine (DA) systems, especially the mesolimbic system, is thought to be critically 
involved in the dependence-producing effects of nicotine. Desensitization of nAChRs is known to 
occur during continuous nicotine exposure. A basic question in the study of nicotine dependence 
is how much nAChR activation and desensitization is caused by the level of nicotine in a 
smoker’s body.  
The purpose of the present study was to evaluate the effects of long-term nicotine 
treatment on brain monoamine transmitters. A mouse model of chronic nicotine administration 
was used, which mimics the nicotine intake of human smokers. Nicotine-containing drinking 
solution was given to mice as the sole source of fluid for 7 weeks, and the daily variation of 
motor activity, cerebral nicotine concentrations and levels of cerebral DA, 5-hydroxytryptamine 
(5-HT), noradrenaline (NA) and pineal melatonin were studied during the chronic treatment. 
Tissue concentrations of DA, NA, 5-HT and their metabolites were measured in different brain 
areas post mortem. The accumbal extracellular concentrations of DA were studied by in vivo 
microdialysis in freely moving mice. 
On the 50th day of nicotine administration, the motor activity of the nicotine-treated mice 
was greater than that of the control mice for a few hours in the forenoon, and after midnight. 
However, the overall daily rhythm of motor activity was not altered. The striatal DA metabolism 
was increased in the nicotine-treated mice in parallel with the enhanced motor activity. 
Simultaneously, elevated extracellular accumbal DA levels were observed in the nicotine-treated 
mice. The nAChR antagonist mecamylamine decreased the accumbal DA levels in the nicotine-
treated but not in the control mice. At some times of the day, increased NA and 5-HT metabolism 
were observed in the nicotine-treated mice with respect to the control mice. Thus, chronic 
nicotine treatment affected the motor activity and brain monoamines as a function of the time of 
day. The effects of chronic nicotine treatment on brain monoamines and motor activity 
disappeared during withdrawal. The daily rhythm of pineal melatonin was not altered by chronic 
nicotine treament. However, the nocturnal pineal melatonin concentrations were slightly lower in 
the nicotine-treated mice than in the control mice.  
The results show that, on the 50th day of nicotine administration, mice consume enough 
nicotine via their drinking water in the active phases of the day to enhance motor activity and 
stimulate accumbal and striatal DA release and metabolism. Thus, even after prolonged nicotine 
administration nAChRs mediating nicotine’s stimulating effects on mesolimbic DA release and 
motor activity are sensitive to nicotine. The findings suggest that the cerebral DA systems are 
important in mediation of nicotine-induced motor hyperactivity in mice. The changes in brain NA 
and 5-HT metabolism observed during chronic nicotine treatment and subsequent withdrawal, 
suggest that all three major monoamine transmitters are involved in nicotine’s 
psychopharmacological effects. Further, the findings suggest that chronic nicotine treatment does 
not alter circadian rhythms in mice maintained on a light-dark cycle. However, the results 
indicate that nAChRs might be involved in the regulation of pineal function.  
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ABBREVIATIONS 
 
ANOVA  analysis of variance 
COMT  catechol-O-methyltransferase 
DA   dopamine 
DHβE   dihydro-β-erythroidine 
DOPAC  3,4-dihydroxyphenylacetic acid  
GABA   γ-aminobutyric acid 
GC-MS  gas chromatography-mass spectrometry 
5-HIAA  5-hydroxyindoleacetic acid 
HIOMT  hydroxyindole-O-methyltransferase 
HPLC   high-performance liquid chromatography 
5-HT   5-hydroxytryptamine, serotonin 
HVA    homovanillic acid 
i.p.   intraperitoneal 
IPn   interpeduncular nucleus 
LC   locus coeruleus 
mAChR  muscarinic acetylcholine receptor 
MAO   monoamine oxidase 
MOPEG  3-methoxy-4-hydroxyphenylethyleneglycol 
3-MT   3-methoxytyramine 
NA   noradrenaline 
nAChR  nicotinic acetylcholine receptor  
NAT   N-acetyltransferase 
NMDA  N-methyl-D-aspartate 
R-GHT  retino-geniculo-hypothalamic tract  
RHT   retinohypothalamic tract 
s.c.   subcutaneous  
SCN   suprachiasmatic nucleus  
SEM   standard error of the mean 
VTA   ventral tegmental area 
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1. INTRODUCTION 
 
Tobacco use, mainly in the form of cigarette smoking, is a worldwide public health 
problem. Cigarette smoking, an important risk factor associated with cancer, 
cardiovascular disease and chronic obstructive pulmonary disease, is the leading 
preventable cause of premature death in developed countries (Peto et al. 1996). Other 
substances than nicotine present in tobacco smoke (e.g. tar and carbon monoxide) are 
most likely responsible for the smoking-related morbidity (Huhtasaari et al. 1992; Sterling 
et al. 1992). Although the initiation of tobacco use may be dependent on social factors, 
this habit is generally considered to be maintained by addiction to nicotine (Stolerman and 
Jarvis 1995). Though smokers are well informed about the hazardous health effects of 
their habit, they frequently fail to quit. It has been estimated that 70 % of all regular 
smokers want to quit smoking, and a majority of them have tried to quit but failed. Less 
than 10 % of those who try to quit are still abstinent after 1 year (Cinciripini et al. 1997). 
 
The neural mechanisms that mediate the effects of nicotine are complex and not fully 
understood. Nicotine seems to share many of the properties of other psychostimulant 
drugs of abuse such as cocaine and amphetamine (Balfour et al. 1998; Wise and Bozarth 
1987). In particular, nicotine has been shown to stimulate the mesolimbic dopamine (DA) 
system, which is critically involved in the reinforcing effects of addictive drugs. In 
addition, the actions of nicotine on several other classical neurotransmitters in the brain, 
including noradrenaline (NA), 5-hydroxytryptamine (5-HT), γ-aminobutyric acid 
(GABA) and glutamate, may partially mediate nicotine’s addictive effects. Nicotine’s 
effects in the nervous system are mediated by the nicotinic acetylcholine receptors 
(nAChRs), a subset of the receptor sites for acetylcholine. Recent findings on the 
structural and functional diversity of nAChRs in the brain have led to numerous attempts 
to clarify their role in several brain functions and behaviours, including neurological and 
mental disorders, as well as nicotine dependence. A basic question in the study of nicotine 
dependence is how much nAChR activation and inactivation is caused by a smoker’s level 
of nicotine. 
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In order to develop better aids for smoking cessation, an increased understanding of the 
mechanisms underlying nicotine dependence is crucial. The study of nicotine dependence, 
like that of other drug dependencies, profits from animal models, which offer the 
possibility to examine the biochemical and behavioural consequences of chronic drug 
treatment at a depth not possible with human studies. Adequate mouse models of nicotine 
dependence would increase the usefulness of genetically modified mouse strains to 
dissecting the neurobiological mechanisms of nicotine dependence. The route of drug 
administration is an important consideration when studying the effects of chronic nicotine 
treatment. Continuous infusions or intermittent injections are the most common routes 
used. In the present study, nicotine was administered to mice in their drinking water 
continuously for several weeks. This method of nicotine delivery mimics the daily pattern 
of smokers’ nicotine intake, which also occurs mainly during the active phase of the day. 
The effects of 7-weeks of nicotine treatment and its subsequent withdrawal on the levels 
of cerebral transmitter monoamines and motor behaviour were examined. In addition, the 
effects of chronic nicotine treatment on various circadian rhythms were studied.  
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2. REVIEW OF THE LITERATURE 
 
2.1. Drug dependence 
 
The terms drug addiction and drug dependence have many colloquial meanings. As a 
scientific term drug addiction is usually described as a compulsion to take a drug with loss 
of control over drug intake. In the Diagnostic and Statistical Manual of Mental Disorders 
1994 (DSM-IV), The American Psychiatric Association defines substance dependence as 
a maladaptive pattern of substance use, leading to clinically significant impairment or 
distress when three (or more) of the following criteria are fulfilled at any time in the same 
12-month period: 1) tolerance, as defined by either a need for markedly increased 
amounts of the substance to achieve intoxication or desired effect, or markedly 
diminished effect with continued use of the same substance, 2) withdrawal, as manifested 
by either the characteristic withdrawal syndrome for the substance, or the same (or a 
closely related) substance being taken to relieve or avoid withdrawal symptoms, 3) the 
substance being taken in larger amounts or over a longer period than was intended, 4) a 
persistent desire or unsuccessful efforts to cut down or control substance use, 5) a great 
deal of time spent in activities necessary to obtain the substance, use the substance (e.g. 
chain-smoking), or recover from its effects, 6) important social, occupational, or 
recreational activities are given up or reduced because of substance use, and 7) the 
substance use continues despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance 
(American Psychiatric Association 1994). The DSM-IV diagnostic criteria are exclusively 
operational though, and do not describe the complex neurobiological mechanisms 
involved in drug addiction. The term addiction is not clearly defined, but usually refers to 
dependence as defined by DSM-IV. However, the term is sometimes used specifically for 
a state of severe dependence (Hyman and Malenka 2001; Jaffe 1985).  
 
Important phenomena associated with dependence-producing drugs are tolerance and 
sensitization. The development of tolerance is not specific to dependence-producing 
drugs, but the development of tolerance to aversive effects of drugs may be of importance 
for their dependence-producing properties. Sensitization (reverse tolerance) is defined as 
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an increase in the effect of a certain amount of drug after repeated administration, or 
inversely, achievement of the same effect by a smaller dose of the substance. Sensitization 
is more likely to occur with intermittent exposure to a drug, in contrast with tolerance, 
which is more likely to occur with continuous exposure (Koob 1996). The physiological 
adaptations caused by chronic drug exposure also result in physical withdrawal 
symptoms, which are relieved when the drug is consumed again. The existence of 
physical withdrawal symptoms is associated with physical dependence, and is not specific 
to drugs of abuse (Jaffe 1985). Positive reinforcing effects of drugs are critical for 
establishing self-administration behaviour and continue to have an important role in all 
aspects of drug dependence, but the mechanisms underlying the transition from initial 
drug use to drug dependence are not clear. It has been hypothesized that the transition to 
drug dependence involves neuroadaptations within brain circuitries that produce positive 
reinforcement. These neuroadaptations may contribute to a negative affective state upon 
drug termination. One mechanism of maintaining drug dependence would be to induce 
continued drug use through negative reinforcement processes to avoid a negative affective 
state (Koob 1996).  
 
2.2. Nicotine dependence 
 
2.2.1. Pharmacokinetics of nicotine 
 
The addictive effects of nicotine depend on the pharmacokinetics of the dosing form. 
Nicotine is rapidly absorbed through tissue barriers and pulmonary alveoli following 
smoke inhalation to the lungs. Inhaled nicotine produces an almost instantaneous bolus in 
arterial blood and is delivered to the brain within 10 s (Russell and Feyerabend 1978). 
This rapid arterial nicotine increase following each inhalation may be especially relevant 
to the reinforcing properties of cigarette smoking as compared to other forms of drug 
delivery. Oral absorption from oral snuff or nicotine gum is gradual, with blood levels 
peaking at the end of the chewing or snuff-taking period. As a base, nicotine is poorly 
absorbed from the stomach, but is well absorbed in the small intestine. The oral 
bioavailability of nicotine is about 45 %. Bioavailability is incomplete because of first-
pass metabolism (Benowitz et al. 1990). Nicotine is widely distributed in all body tissues 
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and organs, with the highest concentrations observed in the brain, lungs, heart, kidneys, 
adrenal glands and liver (Benowitz and Jacob 1999; Schmiterlöw et al. 1967). Nicotine 
undergoes extensive metabolism primarily in the liver, but also to a lesser extent in the 
lung and brain. Approximately 70-80 % of nicotine is metabolised to cotinine and about 4 
% to nicotine-N-oxide. The plasma half-lives of nicotine and cotinine in humans are 2 h 
and 20 h respectively (Benowitz et al. 1990). The plasma half-lives of nicotine and 
cotinine respectively in rats are 1 h and 5-6 h (Miller et al. 1977) and in mice 6-7 min and 
20-40 min (Petersen et al. 1984).  
 
2.2.2. Nicotine and smoking 
 
Human smoking is characterised by intermittent peak concentrations of nicotine with each 
cigarette smoked, superimposed on a low, steady-state baseline level. As the day 
progresses baseline nicotine levels rise, and the influence of peak levels becomes less 
significant. Blood or plasma nicotine concentrations sampled in the afternoon in smokers 
range from 10-50 ng/ml (0.1-0.3 µM). The increment in venous blood nicotine 
concentration after smoking a single cigarette ranges from 5 to 30 ng/ml, depending on 
how the cigarette is smoked. If a smoker smokes until bedtime, measurable nicotine levels 
persist all night (Benowitz et al. 1990).  
 
The view that nicotine is a powerfully addictive drug was summarised in the US Surgeon 
General’s Report in 1988 (US Department of Health and Human Services 1988). Smokers 
experience intravenously administered nicotine as rewarding (Henningfield and Goldberg 
1983), and mecamylamine, a non-competitive nAChR antagonist (Decker et al. 1995), 
increases the number of cigarettes consumed by smokers (Nemeth-Coslett et al. 1986; 
Stolerman et al. 1973b). When smokers are given cigarettes with a different nicotine 
yield, they change the way they smoke the new cigarettes, so as to produce the usual 
nicotine level (Kolonen 1992; Scherer 1999). Nicotine addiction differs from addiction to 
other drugs in that nicotine has effects on anxiety, cognition and feeding behaviour, which 
adds to its abuse potential (Picciotto 1998). Many smokers experience a withdrawal 
syndrome upon smoking-cessation. The nicotine withdrawal syndrome has been described 
in detail, and includes symptoms of anxiety, irritability, difficulty in concentrating, sleep 
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disturbances, and increased hunger and weight gain. Strong tobacco cravings are also 
common (Hughes et al. 1991; Hughes and Hatsukami 1986; Shiffman and Jarvik 1976). 
The onset of withdrawal syndrome begins within a few hours after the last cigarette, and 
includes an increased tendency to smoke, impaired cognitive function, and altered 
electrocortical function (Pickworth et al. 1989). Withdrawal symptoms peak within a few 
days, and then begin to recede over the next several weeks. Some withdrawal symptoms, 
particularly cravings and increased hunger and weight gain, may persist for months or 
more in some individuals (Hughes et al. 1991). Nicotine replacement medication 
alleviates withdrawal symptoms (Cinciripini et al. 1997). 
 
The prevalence of smoking in the general population in the industrial world is 20–50 % 
(Collishaw and Lopez 1996; Fagerström 2002). Patients with mental illness have a higher 
incidence of smoking than the general population. The incidence of smoking is highest in 
schizophrenics, among whom 70 to 90 % are smokers (Hughes et al. 1986). The incidence 
of smoking is also higher in patients with depression or anxiety disorders than in the 
general population (Glassman 1993). These correlations are likely due to common 
mechanisms underlying both substance abuse and many psychiatric disorders, and 
smoking may be an attempt to self-medicate a neurochemical abnormality (Nisell et al. 
1995; Dalack et al. 1998). Also, it has been suggested that smoking may be a way for the 
schizophrenic patients to modulate medication side effects, since smoking increases the 
metabolism of antipsychotic drugs (Ereshefsky et al. 1985; Jann et al. 1986). Smokers 
with a history of major depression who attempt to stop smoking have a higher risk of 
failure than non-depressed smokers, and also an increased risk for developing a new 
episode of major depression after smoking cessation (Glassman et al. 1993; Glassman et 
al. 2001). Interestingly, it has recently been shown that nicotine has an antidepressant 
effect in non-smoking humans (Salin-Pascual and Drucker-Colin 1998; Salin-Pascual et 
al. 1996) and in animal models of depression (Semba et al. 1998; Tizabi et al. 1999). 
Some antidepressants (bupropion and nortriptyline) also aid smoking cessation (Hughes et 
al. 2002). 
 
Several studies have reported an inverse association between cigarette smoking and 
Parkinson’s disease (Baron 1986; Gorell et al. 1999; Morens et al. 1995). Parkinson’s 
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disease is associated with severe loss of DA-containing neurons of the substantia nigra. 
The beneficial effects of nicotine may include neuroprotective effects and stimulation of 
DA release (Balfour and Fagerström 1996; Lindstrom 1997). The epidemiological data 
regarding a possible negative association between cigarette smoking and Alzheimer’s 
disease are controversial (Kukull 2001; Wang et al. 1999). However, both Alzheimer’s 
and Parkinson’s diseases are associated with a loss of nAChRs from the brain (Paterson 
and Nordberg 2000). Thus, nAChRs are interesting therapeutical targets for new 
treatments of these neurodegenerative disorders (Lloyd and Williams 2000). 
 
2.3. Nicotinic acetylcholine receptors  
 
2.3.1. Structure, classification and distribution of nAChRs 
 
Nicotinic acetylcholine receptors (nAChRs) belong to the superfamily of ligand-gated ion 
channels that includes GABAA, glycine and 5-HT3 receptors (Lindstrom et al. 1996; 
McGehee and Role 1995; Paterson and Nordberg 2000; Sargent 1993; Stroud et al. 1990). 
Our current understanding of the structural, molecular and biophysical properties of brain 
nAChRs has arisen largely from studies of the nAChRs in vertebrate muscle cells and 
Torpedo electric organs (Galzi et al. 1991). The receptors have a pentameric structure 
composed of five subunits, assembled around a central pore, which is permeable to 
sodium, potassium and calcium ions (Cooper et al. 1991). Diverse nAChR subtypes are 
formed from different combinations of genetically distinct subunits (Heinemann et al. 
1991). nAChRs present at the neuromuscular junction are composed of two α1 and one 
each of β1, δ and either γ (fetal) or ε (adult) subunits. Neuronal nAChRs are composed of 
α and β subunits (Karlin and Akabas 1995). To date, 12 neuronal subunits (α2-α10 and 
β2-β4) have been identified in rat, chick and human. nAChRs present in the mammalian 
brain are composed of α2-α7 and β2-β4 subunits (Elgoyhen et al. 2001; McGehee and 
Role 1995). The α subunits contain two adjacent cysteines that contribute to the agonist 
binding site, whereas the non-α or β subunits lack these residues but contribute to the 
complementary component of the binding site, and affect the pharmacological properties 
of the receptor (Chavez-Noriega et al. 1997; Luetje and Patrick 1991). The α7 subunits 
form functional homomeric receptors, when expressed in Xenopus oocytes (Couturier et 
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al. 1990), while the α2, α3 and α4 subunits form functional heteromeric receptors when 
expressed in combination with either β2 or β4. The α5 and β3 subunits have been found to 
form functional nAChRs only in combination with other α/β combinations (Deneris et al. 
1989; Lindstrom 2000). The α6 subunit has been shown to form functional nAChRs in 
combination with β2 or β4, but seems to function more effectively in combination with 
another α and a β subunit (Gerzanich et al. 1997; Kuryatov et al. 2000). Some evidence 
exists that the α7 subunit can also be incorporated in more complex combinations (Girod 
et al. 1999).  
 
Fig. 2-1. Schematic organisation of neuronal nAChRs. A: Transmembrane topology of a 
single subunit (Modified from Berkovic et al. 1999). nAChRs results from the assembly 
of five subunits around a central pore. B: Compositions of heteromeric and homomeric 
nAChRs. The most abundant brain nAChR is the α4β2 subtype. 
 
The nAChR subunits are expressed differentially in the brain. In situ hybridisation in the 
rat brain shows that the α4, β2 and α7 mRNAs are widely expressed. The α3 and α5 
mRNAs are less ubiquitous, and the α2, α6, β3 and β4 mRNAs are found only in a few 
brain structures (Lena and Changeux 1998; Wada et al. 1989). Interestingly, the α6 
subunit mRNA is selectively concentrated in catecholaminergic nuclei of the midbrain, 
including the locus coeruleus, the ventral tegmental area (VTA), and the substantia nigra 
(Le Novere et al. 1996).  
 
The endogenous subunit compositions of nAChRs in the brain are not yet fully identified. 
Individual neurons express multiple types of nAChRs (Alkondon and Albuquerque 1993; 
Horch and Sargent 1995; Klink et al. 2001), and adjacent neurons may express different 
 16
combinations of nAChR subtypes (Dani et al. 2000; Lindstrom 1999). Radioligand 
binding studies have distinguished two main categories of nAChRs in the rodent brain on 
the basis of their high affinity for either nicotine or α-bungarotoxin (Clarke et al. 1985b; 
Marks et al. 1986b; Romano and Goldstein 1980; Wonnacott 1986). nAChRs expressed in 
vivo have so far been classified into four main groups based on electrophysiological 
experiments and ligand binding studies in nAChR subunit knock-out and wild-type 
animals (Table 2-1) (Zoli et al. 1998). This classification somewhat extends the previous 
classification described using other methods (Alkondon and Albuquerque 1993). The α-
bungarotoxin binding sites are considered to represent the α7-containing nAChRs (Clarke 
et al. 1985b; Orr-Urtreger et al. 1997; Seguela et al. 1993). This receptor type (Type 1) is 
distributed throughout the brain with a prevalent location in the cortex and limbic areas. 
The high-affinity nicotine binding sites that correspond to β2-containing nAChRs (Type 
2) are distributed throughout the brain, with high levels in the thalamus, moderate levels 
in the cortex, and lower levels in the hippocampus, and are also labelled by epibatidine 
and cytisine (Picciotto et al. 1995; Zoli et al. 1998). The composition of the major isoform 
of this receptor group is α4β2 (Flores et al. 1992; Wada et al. 1989). Some high-affinity 
nicotine binding, persistent in α4 but not β2 knockout mice, demonstrates that minor 
populations of non-α4/β2 containing receptors are present in a few brain nuclei, including 
the interpeduncular nucleus (IPn) and substantia nigra. These binding sites are most likely 
formed by α2/β2 containing receptors in the IPn and α6/β2 containing receptors in the 
catecholaminergic nuclei (Le Novere et al. 1996). Also, other subunits, such as α3, α5 and 
β3 may be incorporated in the Type 2 receptors. Type 3 receptors do not contain either the 
α4 or β2 subunits. This receptor group binds epibatidine with high affinity in equilibrium 
binding experiments but not nicotine or cytisine. A composition of α3β4 is proposed for 
type 3 receptors, and this isotype has been clearly identified in the dorsal medulla 
oblongata, in the pineal gland and in the habenulo-interpeduncular system. Type 4 
receptors do not contain β2, and bind epibatidine and cytisine with high affinity in 
equilibrium binding experiments. Type 4 nAChRs also exhibit faster desensitization than 
Type 3 nAChRs at high doses of nicotine. This receptor group can be found in the 
habenulo-interpeduncular system, and the putative subunit composition may be α2 and/or 
α4 with β4 (Marubio and Changeux 2000; Zoli et al. 1998). 
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Table 2-1. Four classes of nAChRs in rodent brain 
 
Class Putative subunit 
composition 
Localization in 
brain 
Ligand binding 
profile 
Electrophysiological 
response 
Type 1 α7 Throughout brain α-Bgt α-Bgt- and MLA-
sensitive, very 
fast desensitization 
Type 2 β2/α4 
β2/α2?(non α4) 
β2/α3? 
β2/α6/β3? 
 
Throughout brain 
IPn 
Hippocampus 
Catecholaminergic 
nuclei 
EPI>NIC= 
CYT= 
MCC= 
ACh 
MLA-insensitive, 
NIC>>CYT,  
DHβE = MCA 
Type 3 β4/α3/α5? MHb, IPn, dorsal 
medulla, 
pineal gland 
EPI MLA-insensitive 
CYT=NIC, 
DHβE<MCA, 
Slow decay at 100 
µM NIC 
Type 4 β4/α4? 
β4/α2? 
Lateral MHb 
Dorsal IPn 
EPI>CYT> 
MCC=ACh 
MLA-insensitive 
CYT=NIC, 
DHβE<MCA, 
Fast decay at 100 µM 
NIC 
α-Bgt= α-bungarotoxin, CYT=cytisine, DHβE=dihydro-β-erytroidine, EPI=epibatidine, 
MCC=methylcarbamylcholine, MCA=mecamylamine, MLA=methyllycaconitine, 
NIC=nicotine; IPn=interpeduncular nucleus, MHb=medial habenula,  
Based on Zoli et al. (1998), Picciotto et al. (2000) and Marubio and Changeux (2000). 
 
Physiological activation of nAChRs depends on signals deriving from cholinergic cells. 
Cholinergic systems provide diffuse innervation to practically all of the brain, but a 
relatively small number of cholinergic neurons innervate each neural area. There are two 
major cholinergic projection systems. One system arises from neurons in the 
pedunculopontine tegmentum and the laterodorsal pontine tegmentum, and innervates 
mainly the thalamus and midbrain areas and the brainstem. The second major system 
arises in the basal forebrain and projects mainly to the cortex and hippocampus. In 
addition, a population of large cholinergic interneurons is present in the caudate-putamen, 
nucleus accumbens, olfactory tubercle, and Islands of Calleja. The abundance of nAChRs 
in the brain is ten-fold lower than that of muscarinic acetylcholine receptors (mAChRs) 
(Cooper et al. 1996; Zoli 2000). However, nAChRs are present on many types of neurons, 
and are localised both on the cell bodies and/or the dendrites, as well as on axon terminals 
(Wonnacott 1997). There is scant evidence for nicotinic synaptic transmission in the brain 
(Clarke 1993; Role and Berg 1996), but there is plenty of evidence for presynaptic 
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nAChRs that can modulate the release of many transmitters, including DA, NA, 5-HT, 
acetylcholine, GABA, and glutamate (Gray et al. 1996; McGehee and Role 1995; 
Wonnacott 1997). There are undoubtedly postsynaptic nAChRs on neurons in many areas 
of the brain (Colquhoun and Patrick 1997), but it is unclear whether the postsynaptic 
nAChRs mediating responses to exogenously applied nicotinic agonists are involved in 
synaptic transmission (Sorenson et al. 1998).  
 
2.3.2. Activation and desensitization of nAChRs 
 
Resting nAChR channels open in response to agonist binding for several milliseconds to 
allow passage of ions, generally resulting in depolarisation of the neuron. Upon prolonged 
presence of agonist, the channel changes conformation to a desensitized, closed-channel 
state, refractory to activation. This desensitized form of the receptor is not only inactive, 
but has higher affinity for agonist. Recovery from this state occurs after the agonist has 
been removed (Lena and Changeux 1998; Magleby and Pallotta 1981). The phenomenon 
of nAChR desensitization was first characterized at the neuromuscular junction by Katz 
and Thesleff (Katz and Thesleff 1957). According to the “allosteric model” (Monod et al. 
1965), short agonist pulses stabilize the receptor in the active conformation. In contrast, 
prolonged exposures stabilize it in one or more desensitized states, which leads to a 
progressive reduction in the fraction of receptors in the active (open) state (Fig. 2-2). The 
result is a decline of the agonist-evoked current (Buisson et al. 2000). Furthermore, there 
is evidence that nAChRs undergo a more longer-lasting loss of function, termed 
“persistent inactivation”, which is distinct from desensitization. This state persists even 
after removal of agonist (Aoshima 1984; Ke et al. 1998; Rowell and Duggan 1998). The 
pharmacological and kinetic characteristics of the different conformational states depend 
on the subunit composition of the nAChRs (Lena and Changeux 1998). Desensitization 
can occur both at activating and subactivating agonist concentrations (Grady et al. 1994; 
Rowell and Hillebrand 1994). In tobacco use both activation and desensitization of 
nAChRs occur, and both processes probably contribute to the cellular events that underlie 
nicotine dependence (Dani and De Biasi 2001). Desensitization of the nAChRs may offer 
an explanation for the tolerance to some behavioural and biochemical effects in 
experimental animals following prolonged nicotine treatment (Marks et al. 1983), as well 
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as tolerance to some of nicotine’s effects in human tobacco users (Lindstrom 1997). 
Chronic nicotine treatment differentially affects the desensitization and inactivation of 
different nAChR subtypes. In vitro studies on oocytes have shown that, whereas chronic 
nicotine exposure effectively inactivates the α4β2 and α7 subtypes, the subtypes 
containing α3 are fairly resistant to desensitization (Hsu et al. 1996; Olale et al. 1997). 
 
 
 
Fig. 2-2. Multiple functional states of the nAChR. R represents the resting state; A 
represents the active state with the channel open; D1, D2 and D3 represent desensitized 
states (refractory to activation and with high affinity for the nicotinic ligands) (Lena and 
Changeux 1993). 
 
2.3.3. Up-regulation of nAChRs 
 
Increased high-affinity nicotine binding in rodent brain in response to chronic nicotine 
treatment is well documented (Flores et al. 1992; Larsson et al. 1986; Marks et al. 1983; 
Pietilä et al. 1998; Schwartz and Kellar 1983). This up-regulation of receptor number is 
dose-dependent (Marks et al. 1983; Rowell and Li 1997). The doses of nicotine required 
to induce an increase in the number of nicotine binding sites vary with species (Marks 
1999). In rats, nicotine binding sites increase substantially following relatively mild 
treatments, such as twice daily injections (Collins et al. 1988b; Schwartz and Kellar 
1983), or fairly low concentration cotinuous infusion (Fung and Lau 1988). In mice, 
however, Pauly et al. reported that three daily injections had no measurable effect on the 
number of binding sites (Pauly et al. 1992). The levels of continuous-treatment doses of 
nicotine required to increase the density of nAChRs are also reported to be higher in mice 
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than in rats (Marks 1999). Low-affinity nicotine binding measured by [125I]-α-
bungarotoxin binding, is increased only at higher nicotine concentrations than those 
required to increase high-affinity nicotine binding (Marks et al. 1983). That finding is 
consistent with studies on human neuroblastoma cell line SH-SY5Y nAChRs and on 
nAChRs expressed in oocytes, which showed that higher nicotine concentrations are 
needed to up-regulate α7- or α3-containing receptors than to up-regulate α4β2 receptors 
(Fenster et al. 1999; Peng et al. 1997). Increased number of [3H]-nicotine binding sites has 
also been identified in brains from smokers post mortem (Benwell et al. 1988; Breese et 
al. 1997; Court et al. 1998). It has been proposed that chronic administration of nicotine 
results in nAChR up-regulation because nicotine produces receptor desensitization, such 
that nicotine acts as a functional antagonist. Indeed, chronic administration of the non-
competitive antagonist mecamylamine also increased the density of nAChRs (Collins et 
al. 1994; Peng et al. 1994). However, it has also been shown that desensitization alone is 
not sufficient for up-regulation to occur (Rowell and Li 1997). The mechanism by which 
chronic nicotine exposure leads to receptor up-regulation is not known. Chronic nicotine 
or mecamylamine treatment increased nicotine binding in several brain areas of mice 
without increasing the levels of α2, α3, α4, α5 or β2 mRNA, indicating that increased 
receptor number results from post-transcriptional mechanisms (Marks et al. 1992; Pauly 
et al. 1996). It appears that the receptor up-regulation results from a decrease in the rate of 
turnover of the nAChRs on the cell surface (Peng et al. 1994). Whereas several in vitro 
electrophysiological studies on oocytes or cell lines have shown that up-regulation of 
nAChRs are related to decreased function (Fenster et al. 1999; Peng et al. 1994), there are 
also data supporting functional up-regulation by chronic nicotine exposure (Buisson and 
Bertrand 2001; Buisson and Bertrand 2002; Wang et al. 1998).  
 
2.4. Brain monoamines 
 
In their classic mapping studies of central monoaminergic cell groups, Dahlström and 
Fuxe designated the various dopaminergic and noradrenergic cell groups with the letter A, 
the serotonergic cell groups with the letter B, and the adrenergic cell groups with the letter 
C (Dahlström and Fuxe 1964). According to the current nomenclature, groups A1-A7 are 
noradrenergic and A8-A15 dopaminergic (Feldman et al. 1997).  
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2.4.1. Dopamine 
 
The long-length mesencephalic dopaminergic system originating in the A8, A9 and A10 
cell groups is the largest dopaminergic system in the brain. The mesostriatal 
dopaminergic system projects from the substantia nigra (A9), VTA (A10), and the A8 
group, located caudally to A9 and partly in the retrorubral nucleus. The dorsal component 
of this system, which is also called the nigrostriatal pathway, ascends via the median 
forebrain bundle and the internal capsule to innervate the caudate-putamen, known as the 
dorsal striatum (Fig. 2-3). The nigrostriatal pathway is vitally important in motor control, 
and degeneration of this system is the key feature of Parkinson’s disease (Feldman et al. 
1997). The mesolimbic dopaminergic system projects mainly from the A10 area to the 
nucleus accumbens (i.e. the ventral striatum), olfactory tubercle and other limbic regions 
such as amygdala, hippocampus and septum. The mesolimbic system is involved in the 
control of motor behaviour, in motivational processes, and in the control of emotions such 
as reward and reinforcement (Fibiger and Phillips 1988; Koob and Swerdlow 1988). The 
mesocortical dopaminergic system originates mainly in the A10 area, and innervates 
limbic cortical areas such as the medial prefrontal, cingulate and entorhinal areas 
(Björklund and Lindvall 1984). 
 
Fig. 2-3. Schematic diagram illustrating the main dopaminergic projections in the rat 
brain. Upper panel depicts the nigrostriatal pathways and lower panel the mesolimbic 
pathways. Acb=nucleus accumbens, CPu=caudate putamen, OT=olfactory tubercle 
(Modified from Feldman et al. 1997). 
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DA is synthesized from the amino acid tyrosine, which is transported into the DA neuron. 
Once tyrosine has entered the neuron, its conversion to L-dihydroxyphenylalanine (L-
DOPA) by the enzyme tyrosine hydroxylase becomes the rate-limiting step in the DA 
biosynthesis. Thereafter, L-DOPA is rapidly converted to DA by the aromatic L-amino 
acid decarboxylase. Synthesized DA is transported into storage vesicles, which release 
DA when an action potential invades the nerve terminal by exocytosis occurring via a 
calcium-dependent process. Active re-uptake into the nerve terminal by transporter 
molecules is critical in terminating DA action. The main metabolites of DA are 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and a small amount of 
3-methoxytyramine (3-MT). The major pathways of DA metabolism are shown in Fig. 2-
4. Within the nerve terminal, DA is converted to corresponding aldehyde by monoamine 
oxidase (MAO). The aldehyde is subsequently oxidised to DOPAC by aldehyde 
dehydrogenase. After diffusing out of the neurons DOPAC can be further metabolised to 
HVA by catechol-O-methyltransferase (COMT) (Cooper et al. 1996; Elsworth and Roth 
1997; Feldman et al. 1997; Sharman 1973). However, little DOPAC is converted to HVA 
in the mouse striatum (Roffler-Tarlov et al. 1971; Sharman 1973). A fraction of the 
released DA is first O-methylated by COMT to 3-MT, and then converted to HVA by 
MAO and aldehyde dehydrogenase (Cooper et al. 1996). Because COMT is confined to 
glial cells and postsynaptic neurons (Männisto and Kaakkola 1999), O-methylated 
metabolites can provide markers for DA release. DOPAC is considered to be an index of 
intraneuronal synthesis and metabolism of DA (Roffler-Tarlov et al. 1971; Westerink and 
Spaan 1982), since a large amount of DOPAC is derived from a newly formed pool of DA 
(Zetterström et al. 1988). The tissue concentration of HVA is considered to indicate the 
sum of DA synthesis, release and metabolism (Westerink 1985).  
 23
 
Fig. 2-4. Majour routes of catabolism of dopamine in the brain. MAO=monoamine 
oxidase; COMT=catechol-O-methyltransferase (Modified from Feldman et al. 1997). 
 
The electrophysiology of midbrain DA neurons has been extensively studied. These cells 
alternate between a state of spontaneous activity and a silent state, which is due to 
temporary hyperpolarisation (Feldman et al. 1997). When cells are active, they exhibit 
two kinds of discharge activity, single spikes, and bursts of two to ten action potentials 
(Grace and Bunney 1984a; Grace and Bunney 1984b). Electric stimulation of the DA 
pathway with a burst pattern has been found to induce a much larger increase in 
extracellular DA concentrations in the terminal areas as compared with a single spike 
pattern (Chergui et al. 1994). Burst activity seems to be due to activation of NMDA type 
glutamatergic receptors on DA neurons (Charlety et al. 1991; Chergui et al. 1993). 
 
The functions of DA are mediated via activation of DA receptors belonging to the family 
of G-protein coupled receptors. DA receptors are subdivided into two main groups, D1-
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like and D2-like receptors, depending on the effects of agonist binding on adenylate 
cyclase activity. The D1-like receptors include D1 and D5, while the D2-like receptors 
include D2, D3 and D4 (Seeman and Van Tol 1994). Both receptor groups are distributed 
heterogeneously throughout the central nervous system with highest densities in the 
striatum, nucleus accumbens, olfactory tubercles, and the substantia nigra pars compacta 
(Levant 1997). DA synthesis and release are regulated by D2-like autoreceptors located on 
terminals of most dopaminergic neurons. There are also somatodendritic DA 
autoreceptors that, when activated, reduce the rate of cell firing (Feldman et al. 1997). In 
addition, postsynaptic DA receptors also regulate neuronal activity in DA neurons 
through feedback pathways (Cooper et al. 1996). 
 
2.4.2. Noradrenaline 
 
Noradrenergic cell bodies can be organized into two major subgroups, the locus coeruleus 
(LC) groups (A4, A6) and the lateral tegmental groups (A1-A3, A5, A7). The 
noradrenergic neurons originating in the LC make up about 70 % of the noradrenergic 
neurons in the brain. The cortical areas receive a noradrenergic innervation that arises 
exclusively from the LC, whereas much of the basal forebrain noradrenergic innervation 
also arises from the LC. The LC innervation to the diencephalon is largely to the dorsal 
thalamus with smaller, restricted projections also to the hypothalamus. Lateral tegmental 
neurons project to the spinal cord and brain stem, whereas the lateral tegmental 
innervation of forebrain is largely restricted to the hypothalamus, with some innervation 
also in the basal forebrain (Fig. 2-5) (Moore and Card 1984). The noradrenergic system 
plays an important role in attention and vigilance, but is also involved in the regulation of 
learning and memory, as well as in anxiety (Grace et al. 1998). NA also seems to be 
critically involved in processes of hunger and satiety (Feldman et al. 1997). 
Noradrenergic neurons originating in the LC have also been implicated in the physical 
aspects of alcohol and opiate withdrawal (Ahtee and Svartström-Fraser 1975; Nestler 
1992). 
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Fig. 2-5. Schematic diagram illustrating the distribution of the main noradrenergic 
pathways in the rat brain. Cb=Cerebellum, Ctx=cortex, HC=hippocampus, 
HT=hypothalamus, Th=thalamus (Modified from Feldman et al. 1997). 
 
The biosynthesis pathway for the formation of NA is shared with that of DA. The enzyme 
dopamine β-hydroxylase, localized in the storage vesicles, converts DA to NA. After NA 
has been released into the synaptic cleft by way of vesicle fusion, it is rapidly taken up 
into the nerve terminal via the NA transporter. The principal pathways of NA metabolism 
are shown in Fig. 2-6. Similar to that of DA, the degradation of NA may begin with either 
deamination or O-methylation. One important difference between NA and DA 
metabolism however, is that in the case of NA, the aldehyde intermediates that are 
produced by MAO, 3,4-dihydroxyphenylglycoaldehyde (DHPGA) and 3-methoxy-4-
hydroxyphenylglycoaldehyde (MHPGA), can either be oxidized to acids or reduced to 
glycols. In the case of brain NA, reduction of the aldehyde metabolites is the favoured 
route of metabolism. The intraneuronal metabolite is 3,4-dihydroxyphenylethyleneglycol 
(DOPEG), which is further O-methylated by COMT to 3-methoxy-4-
hydroxyphenylethyleneglycol (MOPEG) (Cooper et al. 1996; Feldman et al. 1997). 
Patterns of NA metabolism vary considerably among animal species. In the rat brain 
MOPEG exists mostly as the sulphate conjugate, whereas in the mouse brain it is the free 
form of MOPEG, which predominates (Ceasar et al. 1974; Sharman 1973). The amount of 
MOPEG accumulated in the brain may reflect the functional activity of the central 
noradrenergic neurons (Ceasar et al. 1974; Cooper et al. 1996; Heal et al. 1989; Sharman 
1969). 
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Fig. 2-6. Major routes of catabolism of noradrenaline in the brain. MAO=monoamine 
oxidase; COMT=catechol-O-methyltransferase (Modified from Feldman et al. 1997).  
 
In a conscious animal LC noradrenergic neurons fire with a low basal frequency and 
variations in the firing rate are related to the sleep-waking cycle such that the cells are 
almost completely silent during REM sleep (Aston-Jones and Bloom 1981). In addition, 
the firing rate changes as a function of behavioural activity and sensory input. For 
example, neuronal discharge has been found to be reduced during certain behaviours, 
such as in grooming or eating. In contrast, auditory, visual, or somatosensory stimuli all 
elicited biphasic responses consisting of a brief burst followed by a more prolonged 
interval of decreased activity (Feldman et al. 1997). It has been hypothesised that activity 
in LC neurons serves to arouse the organism to a state of vigilance, enabling it to adapt to 
various situations (Grant et al. 1988; Svensson 1987). 
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The adrenoceptors, which are all members of the superfamily of G protein-coupled 
receptors, have classically been divided into two distinct classes called α-adrenoceptors 
and β-adrenoceptors. These can be further divided into α1 (α1A, α1B, α1C, α1D), α2 (α2A, α2B, 
α2C), β1, β2 and β3 subtypes. All subtypes, with the exception of β3, are present in the brain 
in diverse distribution patterns (Nicholas et al. 1996). Some α2-adrenoceptors are found 
on the terminals of noradrenergic fibers, where they serve as release-inhibiting 
autoreceptors. Somatodendritic α2-autoreceptors inhibit the firing of LC neurons much 
like the D2 autoreceptors do in the substantia nigra (Feldman et al. 1997).  
 
2.4.3. 5-Hydroxytryptamine 
 
The serotonergic neurons of the brain stem are conveniently divided into a caudal system 
and a rostral system. The caudal system consists of the B1-B4 cell groups, located in the 
median and paramedian regions of the medulla and caudal pons. These neurons project to 
the medulla and spinal cord along several pathways. The rostral system consists of the 
B5-B9 cell groups, which are associated with the raphé nuclei. The dorsal and median 
raphé nuclei are the major sources of the serotonergic innervation to the forebrain, and 
they supply projections to numerous parts of the diencephalon, basal ganglia, limbic 
system and cortex (Fig. 2-7) (Cooper et al. 1996; Feldman et al. 1997). Brain 5-HT 
systems are involved in the regulation of several functions and behaviours, including 
sleep-wake rhythm, motor functions, mood, pain perception, feeding and aggression. 
Dysfunction of the brain 5-HT system has been implicated in anxiety, affective disorders 
and drug addiction (Feldman et al. 1997; Osborne 1982).  
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Fig. 2-7. Schematic diagram illustrating the distribution of the main serotonergic 
pathways in the rat brain Cb=Cerebellum, CPu=caudate putamen, Ctx=cortex, 
HC=hippocampus, HT=hypothalamus, Th=thalamus (Modified from Cooper et al. 1996). 
 
The first step of 5-HT synthesis is the uptake of the amino acid tryptophan into the 
neuron. Tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by the enzyme 
tryptophan hydroxylase, and then 5-HTP is rapidly decarboxylated to 5-
hydroxytryptamine. Most of the 5-HT is stored in vesicles. The mechanism of 5-HT 
release is usually assumed to be exocytosis. As with the dopaminergic and noradrenergic 
neurons, re-uptake serves as a major mechanism for the termination of action of synaptic 
5-HT. 5-HT is deaminated by MAO to 5-hydroxyindoleacetaldehyde, which is then 
rapidly oxidized by aldehyde dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA), 
which is considered to be the primary metabolite of 5-HT (Fig. 2-8) (Cooper et al. 1996; 
Feldman et al. 1997). It is generally held that 5-HIAA reflects in some measure the 5-HT 
utilization (Hery et al. 1972). However, significant amounts of 5-HIAA can also be 
generated from 5-HT, which was never released. Thus, 5-HIAA levels primarily reflect 
intraneuronal metabolism and only to a minor degree the metabolism of 5-HT released 
from the nerve terminals (Commissiong 1985; Kalen et al. 1988; Wolf et al. 1985). 
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Fig. 2-8. Catabolism of 5-hydroxytryptamine. MAO=monoamine oxidase (Modified from 
Feldman et al. 1997). 
 
The dorsal raphé 5-HT neurons appear tonically active. Their firing rate is the highest 
when the animal is awake, lower during slow-wave sleep, and almost completely 
abolished during REM sleep (Jacobs and Fornal 1991).  
 
The 5-HT receptors in the brain are highly heterogenous. While the majority of receptors 
belong to the large family of receptors interacting with G-protein, the 5-HT3 receptors, are 
ligand-gated ion channels. The 5-HT1 family includes the 5-HT1A, 5-HT1B, 5-HT1D, 5-
HT1E and 5-HT1F receptors. The 5-HT2 receptor family consists of the 5-HT2A, 5-HT2B and 
5-HT2C receptors. In addition, 5-HT4, 5-HT6, and 5-HT7 receptors are also present in the 
brain. The 5-HT1A receptor is the one best characterized. It occurs both pre- and 
postsynaptically in several brain areas, and as a somatodendritic autoreceptor it inhibits 
the firing of 5-HT neurons (Cooper et al. 1996; Feldman et al. 1997). 
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2.5. Nicotine and dopamine 
 
2.5.1. Effects of nicotine on midbrain dopamine systems 
 
nAChRs are present on both the cell soma and the terminal membranes of the mesolimbic 
and nigrostriatal DA systems (Clarke and Pert 1985; Deutch et al. 1987; Schwartz et al. 
1984). A recent study by Klink et al. (Klink et al. 2001) combining single-cell RT-PCR 
and patch-clamp electrophysiology in both wild-type mice, and mice lacking the α4, β2, 
or α7 subunits, showed that most neurons in the midbrain express two nAChR subtypes. 
These two types are thought to be made up of the α4/α5/β2 and the α4/α5/α6/β2 subunits. 
An α7 subunit-containing receptor is also expressed in somewhat less than half of the DA 
neurons. Nicotine increases the firing of midbrain DA neurons both in vitro and in vivo 
(Calabresi et al. 1989; Clarke et al. 1985a; Grenhoff et al. 1986; Pidoplichko et al. 1997). 
In rats and mice acute nicotine elevates the striatal tissue concentrations of DOPAC and 
HVA (Freeman et al. 1987; Haikala et al. 1986; Lapin et al. 1989; Pietilä et al. 1996; Roth 
et al. 1982; Salminen et al. 1999; Salminen and Ahtee 2000). Acute nicotine is also shown 
to elevate the extracellular DA levels in the striatum and nucleus accumbens of rats both 
when administered systemically, and when applied locally to the brain (Damsma et al. 
1989; Imperato et al. 1986; Kiianmaa et al. 2000; Marshall et al. 1997; Mifsud et al. 1989; 
Nisell et al. 1994; Seppä et al. 2000). Nicotine also stimulates the DA release in brain 
slices and in synaptosomes prepared of accumbal or striatal tissue (Giorguieff-Chesselet 
et al. 1979; Grady et al. 1992; Rapier et al. 1988; Rowell et al. 1987; Westfall 1974). The 
DA neurons, which project to the nucleus accumbens, have been found to be more 
sensitive to the stimulatory effects of nicotine than those which innervate the dorsal 
striatum though (Benwell and Balfour 1997; Mereu et al. 1987). Nicotine-induced 
enhancement of DA release has also been observed in the prefrontal cortex (Nisell et al. 
1996). 
 
At least two different nAChR subtypes are involved in the nicotine-induced DA release 
from striatal synaptosomes. One contains α3 and/or α6 and β2 subunits (Champtiaux et al. 
2002; Kaiser et al. 1998; Kulak et al. 1997; Mogg et al. 2002) and the other contains α4 
and β2 subunits (Sharples et al. 2000). From studies of DA release in striatal slices, there 
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is evidence that α7-containing nAChRs on striatal glutamatergic terminals elicit glutamate 
release, which in turn acts on ionotropic glutamate receptors on dopaminergic terminals to 
modulate DA release (Kaiser and Wonnacott 2000). This is supported by the recent 
finding in vivo that the α7 nAChR anatagonists methyllycaconitine and α-bungarotoxin, 
when delivered into the nucleus accumbens, partially inhibited the enhanced DA release 
that was induced by systemically administered nicotine (Fu et al. 2000b). However, 
nicotine-evoked DA release, measured both in vivo and in vitro, is absent in mutant mice 
not expressing the β2 subunit of the nAChR (Grady et al. 2001; Picciotto et al. 1998; 
Zhou et al. 2001). This indicates that β2-containing receptors are necessary for nicotine-
induced DA release, although it does not exclude the possibility that DA release can be 
modulated via α7-containing receptors. Somatodendritic nAChRs seem to be of greater 
importance in regulating the DA release induced by systemic nicotine than nAChRs 
located in the terminal area, since infusion of mecamylamine into the VTA, but not into 
the nucleus accumbens, inhibited nicotine-induced DA release (Nisell et al. 1994). 
Furthermore, there is evidence that nicotine-induced DA release is modulated by nAChRs 
residing on glutamatergic terminals in the VTA, which increase glutamate release, and 
thereby increase burst firing in the DA neurons via NMDA receptors (Erhardt et al. 2002; 
Fu et al. 2000a; Schilström et al. 1998; Schilström et al. 2000).  
 
Various studies have demonstrated that during chronic nicotine treatment, tolerance or 
sensitization to nicotine’s effects on brain DA may develop, depending on the animal 
species, dosing schedule, length of treatment and response measured. In studies utilizing 
repetitive stimulation with nicotine in vitro, attenuation of nicotine-induced [3H]-DA 
release from rat and mice striatal synaptosomes have been observed. This was suggested 
to reflect desensitization of nAChRs, or after high doses or prolonged treatment, even 
long-lasting inactivation (Grady et al. 1994; Rowell and Duggan 1998; Rowell and 
Hillebrand 1994). However, chronic nicotine injections in rats have resulted in increased 
nicotine-evoked DA release from striatal slices (Yu and Wecker 1994), and the nicotine-
induced DA release from striatal synaptosomes was increased in preparations from rats 
treated chronically with the nicotinic agonist anatoxin-a (Rowell and Wonnacott 1990). 
Moreover, Damsma et al. (Damsma et al. 1989) and Nisell et al. (Nisell et al. 1996) found 
no tolerance to the nicotine-induced DA release in the nucleus accumbens in rats they 
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treated once daily with nicotine (0.35-0.5 mg/kg s.c.) for 12-15 days. However, during 
chronic continuous nicotine infusion to rats, either no change (Benwell et al. 1995; 
Hildebrand et al. 1998) or an increase (Carboni et al. 2000; Salminen et al. 1999) of 
accumbal DA release and metabolism was observed. Continuous nicotine treatment via 
the drinking water was found to increase the striatal DA metabolism in mice (Pietilä et al. 
1995). However, tolerance to nicotine’s elevating effect on striatal concentrations of 
DOPAC and HVA was found when a nicotine challenge was given 24 h after withdrawal 
from a chronic oral nicotine treatment (Pietilä et al. 1996). In contrast, an enhanced 
accumbal DA response to a challenge injection of nicotine was observed in rats after 
termination of a chronic nicotine infusion (Benwell et al. 1995).  
 
Shorter treatments of once daily nicotine injections for only 5 days was shown to produce 
enhancement (sensitization) of nicotine-induced DA release in the nucleus accumbens 
(Benwell and Balfour 1992; Cadoni and Di Chiara 2000). Further, when nicotine was 
administered via a microdialysis probe directly into the dorsal striatum or nucleus 
accumbens of rats pre-treated with nicotine, a sensitized response was observed in both 
brain areas after both a 7-day pre-treatment with repeated injections, and after continuous 
infusion-treatment (Marshall et al. 1997). There is evidence that reduced inhibitory 
control of DA neurons by DA autoreceptors is involved in this sensitization phenomenon. 
Also, the development of sensitization seems to be dependent on co-stimulation of 
NMDA glutamatergic receptors (Balfour et al. 1998). Pretreatment with nicotine also 
caused sensitization of the NA-secreting neurons that innervate the hippocampus from the 
locus coeruleus (Benwell and Balfour 1997; Mitchell 1993). This sensitized response was 
associated with increased formation of NA in the nerve terminals (Mitchell et al. 1989; 
Smith et al. 1991). However, that does not seem to be the mechanism underlying the 
development of sensitized DA responses in the nucleus accumbens (Balfour et al. 1998; 
Mitchell et al. 1989). 
 
2.5.2. Effects of nicotine on motor activity 
 
Nicotine has variable effects on locomotor activity depending upon factors such as animal 
species, baseline activity, habituation to the environment, drug dose and duration of 
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treatment. Small doses of nicotine (0.1-1 mg/kg s.c.) increase locomotion in rats that have 
been habituated to the environment (Ksir et al. 1987; O'Neill et al. 1991). Larger doses of 
nicotine in drug-naïve rats produce an initial transient decrease of activity (Clarke and 
Kumar 1983; Morrison and Stephenson 1972). In mice, nicotine usually induces 
locomotor depression (Collins et al. 1988a; Freeman et al. 1987; Hatchell and Collins 
1977; Pietilä et al. 1998). Tolerance towards nicotine’s depressant effect on locomotor 
activity has been shown to develop both in rats (Clarke and Kumar 1983; Falkeborn et al. 
1981; Morrison and Stephenson 1972; Stolerman et al. 1973a) and in mice (Hatchell and 
Collins 1977; Marks et al. 1983; Marks et al. 1986a; Pietilä et al. 1998; Sparks and Pauly 
1999). Tolerance to the locomotor depressant effect of nicotine in mice has been related to 
stimulation of corticoid secretion (Pauly et al. 1990; Robinson et al. 1996). Tolerance to 
the locomotor stimulant effect did not develop after chronic intermittent treatment in rats, 
but in fact such treatment resulted in sensitization of the locomotor stimulant effect 
(Benwell and Balfour 1992; Cadoni and Di Chiara 2000; Clarke and Kumar 1983; Ksir et 
al. 1987; Morrison and Stephenson 1972; Nisell et al. 1996; Shim et al. 2001; Stolerman 
et al. 1973a). However, during continuous nicotine infusion to rats, tolerance to the 
locomotor stimulating effect was shown to develop within 5-6 days (Benwell et al. 1995; 
Morley and Garner 1990).  
 
There is substantial evidence that the locomotor stimulant effects of nicotine in rats are 
the result of its stimulating effect on mesolimbic DA transmission. Lesions of DA 
neurons by infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) in the VTA inhibit 
the locomotor stimulant effect of nicotine (Clarke et al. 1988; Louis and Clarke 1998). 
However, Vezina et al. (Vezina et al. 1994) failed to observe this effect. DA receptor 
antagonists reduced the locomotor stimulant effects of nicotine in doses that did not 
reduce the spontaneous locomotion (Corrigall and Coen 1991; O'Neill et al. 1991). 
Further, locomotor activation was also produced by intra-VTA infusion of nicotinic 
agonists (Leikola-Pelho and Jackson 1992; Panagis et al. 1996; Reavill and Stolerman 
1990), and nicotine-induced locomotion was inhibited by administration of the nicotinic 
antagonist dihydro-β-erythroidine (DHβE) into the VTA (Corrigall et al. 1994). Thus, the 
locomotor stimulant effect of nicotine appears to be initiated by nicotinic receptor 
activation within the VTA, which results in increased DA release in the nucleus 
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accumbens. However, it was recently shown that an increase in accumbal DA levels as 
measured by microdialysis, was not alone sufficient to stimulate locomotor activity, 
because intra-accumbal nicotine administration increased accumbal DA levels, but in 
contrast to intra-VTA or systemic nicotine administration, it did not elicit locomotion. 
Thus, it is possible that coactivation of other DA terminal fields besides the nucleus 
accumbens, such as the dorsal striatum or prefrontal cortex, may be necessary for 
nicotine-elicited locomotion (Ferrari et al. 2002). Recent evidence suggests that α6-
containing nAChRs participate in the locomotor stimulant effect of nicotine (Le Novere et 
al. 1999). The α7 receptor does not seem to be important (Grottick et al. 2000; Kempsill 
and Pratt 2000). 
 
Nicotine’s depressant effect on locomotor activity is thought to be mediated through the 
IPn (Hentall and Gollapudi 1995), and seems to be mediated by different nAChRs 
subtypes than its locomotor stimulating effects (Brioni et al. 1997).  
 
The mechanisms mediating sensitization to the locomotor response of nicotine are not 
fully understood. One old hypothesis is that the depressant and stimulating actions of 
nicotine occur simultaneously, and then with repeated administration the development of 
tolerance to the depressant effect unmasks the stimulating effect (Morrison and 
Stephenson 1972). However, there is evidence that the locomotor sensitization to nicotine 
is a true behavioural sensitization similar to that occurring with other psychostimulants 
(Balfour et al. 1998). The development of sensitization is prevented by coadministration 
of the NMDA receptor antagonist MK-801 (Shoaib et al. 1994), and is accompanied by 
sensitized mesolimbic DA response to nicotine (Benwell and Balfour 1992; Cadoni and 
Di Chiara 2000). However, studies with other NMDA receptor antagonists have shown a 
dissociation between the expression of the sensitized mesolimbic DA response and the 
sensitized locomotor response to nicotine (Balfour et al. 1998), and sensitization of the 
locomotor response to nicotine is not always associated with sensitized mesolimbic DA 
response (Nisell et al. 1996). 
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2.5.3. Nicotine reinforcement 
 
Nicotine elicits drug-seeking behaviour in animal studies as demonstrated by self-
administration and place-preference experiments (Di Chiara 2000a). The conditions under 
which nicotine is self-administered by animals appear to be more restricted than for many 
other drugs of abuse. Intravenous self-administration of nicotine is best demonstrated 
under conditions of limited availability (Henningfield and Goldberg 1983). It has been 
logical to test if a dopaminergic mechanism is involved in nicotine reinforcement, since 
there is a large body of evidence that DA, and in particular the mesolimbic projections, 
play a part in drug reinforcement and motivated behaviour induced by drugs. Indeed, 
stimulation of DA systems appears to be of critical importance for the acute positive 
reinforcing properties of nicotine. DA receptor antagonists attenuate nicotine self-
administration (Corrigall and Coen 1991), and lesions of the DA neurons projecting from 
VTA to the nucleus accumbens with 6-OHDA attenuate nicotine self-administration 
markedly as compared with sham-treated animals (Corrigall et al. 1992; Singer et al. 
1982). Also, micro-infusions of the nicotinic antagonist DHβE into the VTA, but not to 
the nucleus accumbens, produced a significant and dose-related decrease in nicotine self-
administration (Corrigall et al. 1994). These data strongly indicate that the mesolimbic 
DA system is a substrate in nicotine reinforcement, and that nicotine activates this system 
through the VTA. There is also evidence for a role of DA in the effects of nicotine on 
intracranial self-stimulation, and in nicotine-induced place-preference (Di Chiara 2000b). 
 
2.6. Nicotine and noradrenaline 
 
The noradrenergic neurons appear to express nAChRs on both somatodendritic 
membranes in the locus coeruleus, and on the nerve terminals (Balfour 1982; Egan and 
North 1986; Lena et al. 1999). It has been shown in electrophysiological experiments that 
there are two distinct mechanisms by which systemic nicotine activates LC neurons; a 
transient action mediated by peripheral nAChRs on primary sensory fibers and a long-
lasting effect mediated by nAChRs located on LC neurons themselves (Engberg and 
Hajos 1994; Hajos and Engberg 1988). In vitro relatively low concentrations of nicotine 
increase NA release from hypothalamic slices and synaptosomes (Balfour 1973; Hall and 
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Turner 1972; Yoshida et al. 1980) while higher doses are needed to increase NA from 
tissues derived from other brain areas (Balfour 1973; Clarke and Reuben 1996). Systemic 
administration of nicotine increases NA synthesis, metabolism and turnover in the rodent 
brain (Andersson et al. 1980; Bhagat 1970; Fuxe et al. 1977; Mitchell et al. 1990; Tani et 
al. 1997). In microdialysis experiments nicotine has been shown to increase the release of 
NA in the cortex, hypothalamus and hippocampus (Brazell et al. 1991; Sharp and Matta 
1993; Summers and Giacobini 1995). nAChRs in the brainstem seem to be more 
important for the nicotine-induced NA release than presynaptic nAChRs in the terminal 
areas (Fu et al. 1998; Fu et al. 1997; Mitchell et al. 1993). Recently it has been shown that 
NA release in the hypothalamic paraventricular nucleus as measured with microdialysis 
increases during continuous nicotine self-adminstration (Fu et al. 2001).  
 
Both chronic nicotine and a single dose of nicotine were shown to increase the expression 
of mRNA for tyrosine hydroxylase in the LC a few days after the nicotine administration, 
and a prolonged increase in tyrosine hydroxylase activity was observed in the 
hypothalamic and hippocampal terminal areas. The increase in tyrosine hydroxylase 
activity in the terminals four weeks after a single administration was associated 
functionally with an increase in the capacity to release NA in the hippocampus (Mitchell 
et al. 1993; Smith et al. 1991). This effect is mediated by central nAChRs, and seems to 
be specific for the NA neurons, as it was not observed in DA or 5-HT neurons (Mitchell 
et al. 1989). 
 
2.7. Nicotine and 5-hydroxytryptamine 
 
nAChR subunits are expressed in the mesencephalic raphé nuclei, and lesion experiments 
suggest that 5-HT terminals in the striatum and hypothalamus possess nAChRs (Schwartz 
et al. 1984; Wada et al. 1989). Nicotinic binding sites have not been observed on 
serotonergic terminals in the cortex though (Schwartz et al. 1984). Nicotine has been 
shown to increase 5-HT release from striatal slices (Reuben and Clarke 2000; Yu and 
Wecker 1994). However, the nAChR subtypes involved could not be identified. The 
nicotine-stimulated increase in 5-HT release from rat striatal slices was shown to be 
enhanced after 10 days of nicotine pretreatment (Yu and Wecker 1994). Further, 
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Takahashi et al. found that the effects of chronic nicotine on 5-HT release in the striatum 
of rats were enhanced by exposure to stress (Takahashi et al. 1998), and chronic nicotine 
treatment in the drinking water was shown to increase the striatal 5-HT and 5-HIAA 
concentrations in mice (Pietilä et al. 1995). It has also been shown that acute nicotine 
increases 5-HT release in the cortex (Ribeiro et al. 1993; Summers and Giacobini 1995; 
Toth et al. 1992). In contrast, in the hippocampus nicotine has been shown to reduce the 
5-HT output (Balfour and Ridley 2000). Overall, the serotonergic system seems to be less 
sensitive to the effects of nicotine than the dopaminergic and noradrenergic systems. 
There is also a lot of evidence that the basal 5-HT tone is important to the effects of 
nicotine (Rosecrans 1971; Rosecrans 1995; Seth et al. 2002). 
 
It was shown by Mihailescu et al. that the nicotine-induced increase of 5-HT release from 
rat midbrain slices was accompanied by both increases and decreases of the firing rates of 
dorsal raphé neurons (Mihailescu et al. 1998). However, systemically administered 
nicotine was shown to inhibit the firing activity of dorsal raphé 5-HT neurones in 
anaesthetised animals. The inhibition was blocked with a selective 5-HT1A receptor 
antagonist (WAY 100635), indicating nicotine-induced 5-HT release, and a possible 
involvement of somatodendritic 5-HT1A receptors in the effect of nicotine. This effect of 
nicotine was suggested to be an indirect effect on 5-HT neurons, possibly by involving 
afferent pathways, since microiontophoretic application of nicotine into the dorsal raphé 
failed to inhibit 5-HT neurons (Engberg et al. 2000). Interestingly, the actions of nicotine 
on dorsal raphé neurons resemble those of selective 5-HT re-uptake inhibitors, which, like 
nicotine, inhibit the firing rate of dorsal raphé neurons (Arborelius et al. 1995), and 
increase extracellular levels of 5-HT in various forebrain areas (Invernizzi et al. 1997). 
Additionally, the 5-HT1A receptors in the dorsal raphé nucleus are proposed to play a role 
in mediating the anxiolytic effects of nicotine (Seth et al. 2002). Although some reward-
related behaviours, such as behavioural sensitization and nicotine-induced place 
preference, are modified by 5-HT manipulation (Carboni et al. 1989; Olausson et al. 
2002), there is no direct evidence for 5-HT involvement in nicotine reinforcement. 
However, the possible involvement of 5-HT in nicotine’s anxiolytic and antidepressant 
effects suggests that brain 5-HT plays some role in nicotine dependence.  
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2.8. Nicotine withdrawal 
 
The nicotine withdrawal syndrome in both humans and rodents has somatic and affective 
aspects (Kenny and Markou 2001). Spontaneous withdrawal from chronic nicotine 
infusion in rats has been shown to result in a physical abstinence syndrome characterized 
by teeth-chattering, chews, writhing, gasps, tremors, shakes, ptosis and yawning. This 
syndrome was observed during the first 2 days of withdrawal, and was alleviated by a 
single dose of nicotine. A significant drop in locomotor activity on the first day of 
withdrawal and an increase in weight gain were also observed (Malin et al. 1992). A 
similar abstinence syndrome was also observed in mice withdrawn from a 14-day 
treatment of repeated large doses of nicotine (2 mg/kg four times a day) (Isola et al. 
1999). In addition, a nicotine abstinence syndrome was also precipitated by administration 
of various nAChR antagonists such as mecamylamine and DhβE to rats during chronic 
nicotine infusion (Hildebrand et al. 1997; Malin et al. 1994; Malin et al. 1998). 
 
It is unclear what neurotransmitter system is involved in mediating somatic aspects of 
nicotine withdrawal. The nicotine abstinence syndrome displays some similarities with 
the opiate abstinence syndrome (Malin et al. 1988), and the somatic signs of nicotine 
withdrawal could be precipitated by the opiate antagonist naloxone (Carboni et al. 2000; 
Malin et al. 1993). There is a considerable amount of evidence suggesting that NA plays a 
major role in mediating somatic signs in rats undergoing opiate withdrawal (Maldonado 
1997). Moreover, the α2-adrenoceptor agonist clonidine, which acts to decrease 
noradrenergic neurotransmission has shown efficacy in smoking cessation trials (Gourlay 
et al. 2002). It is therefore possible that NA may be involved in mediating somatic signs 
in rats undergoing nicotine withdrawal, although further studies are required to address 
this possibility (Kenny and Markou 2001).  
 
Spontaneous and precipitated nicotine withdrawal results in elevations in brain reward 
thresholds, which reflect diminished sensitivity to rewarding stimuli, similar to that seen 
with other drugs of abuse (Epping-Jordan et al. 1998). The decrease in reward function 
observed during nicotine withdrawal is centrally mediated, whereas the somatic 
withdrawal syndrome appears to be both centrally and peripherally mediated (Hildebrand 
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et al. 1997; Watkins et al. 2000). In addition, precipitated nicotine withdrawal induces 
conditioned place aversion, in which the opioid system seems to be involved (Watkins et 
al. 2000). Spontaneous and antagonist-precipitated withdrawal from various drugs of 
abuse has been shown to produce marked deficits in accumbal DA release (Rossetti et al. 
1992). Also, Hildebrand et al. have shown that mecamylamine significantly decreases 
accumbal extracellular DA levels in rats chronically treated with nicotine (Hildebrand et 
al. 1998), and decreased tissue levels of DA in the striatum and nucleus accumbens have 
been found during spontaneous nicotine withdrawal in rats (Fung et al. 1996). It has been 
proposed that decreases in accumbal DA output observed during drug withdrawal are 
specifically related to reward and motivational deficits such as elevations in brain 
stimulation reward thresholds, but not to somatic withdrawal signs (Kenny and Markou 
2001). In addition, deficits in 5-HT neurotransmission seem to be involved in mediating 
elevations in brain reward thresholds and in increased anxiety during nicotine withdrawal 
(Costall et al. 1993; Costall et al. 1990; Harrison et al. 2001).  
 
2.9. Nicotine, circadian rhythms and melatonin  
 
The existence of a daily rhythm is apparent in many behavioural and physiological events 
and parameters, including physical activity, sleep, body temperature, and levels of 
hormones and transmitters. Rhythms with a period of approximately 24 hours are called 
circadian (Minors and Waterhouse 1986). These rhythms are driven by the biological 
clock system located in the hypothalamic suprachiasmatic nucleus (SCN), which is 
entrained to external time cues. The light-dark cycle is the main environmental cue 
entraining the clock and the rhythms driven by it. The SCN receives input from the retina 
directly via the retinohypothalamic tract (RHT), and indirectly via the retino-geniculo-
hypothalamic tract (R-GHT) via the intergeniculate leaflet. A third major afferent system 
to the SCN arises from the raphé nucleus. Excitatory amino acids are thought to be the 
primary transmitter in the RHT, GABA and neuropeptides are important in the R-GHT, 
and 5-HT is the major transmitter of the raphé projection (Hastings 1997). In addition, 
many other neuroactive substances have been identified in the SCN, one of which is 
acetylcholine (Rusak and Bina 1990). There is substantial evidence suggesting that 
cholinergic stimulation of the SCN alters behavioural circadian rhythms (Colwell et al. 
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1993; Earnest and Turek 1985; Zatz and Herkenham 1981). However, it is unclear 
whether mAChRs or nAChRs (or both) mediate these effects since carbachol, which 
stimulate both receptor types, has most commonly been used (O'Hara et al. 1998). The 
early work of Miller et al. demonstrated that suprachiasmatic neurons are responsive to 
nicotinic stimuli (Miller et al. 1987). More recently, acute nicotine has been shown to 
cause phase delays in the drinking rhythm (O'Hara et al. 1998) and in the timing of the 
onset of melatonin excretion (Ferguson et al. 1999) in rats. However the overall daily 
rhythm of motor activity in rats was not affected by nicotine (Kita et al. 1985; Morley and 
Garner 1990). In humans, the circadian system and cigarette smoking also appear to 
interact (O'Hara et al. 1998). Smoking varies considerably over the course of a day for 
most smokers (Hasenfratz et al. 1992) and some data suggest that peak activity may be 
altered in smokers (Jacober et al. 1994). In addition, chronic smokers have greater 
problems falling asleep and staying asleep, and also report greater daytime sleepiness 
(Phillips and Danner 1995; Wetter and Young 1994). However, no difference in the 
circadian rhythm of salivary cortisol was found between smokers and nonsmokers 
(Kirschbaum et al. 1994). 
 
One of the most clearly fluctuating functions is melatonin secretion from the pineal gland. 
The pineal gland is a small neuroendocrine organ located in the centre of the skull 
between the two cerebral hemispheres. Photic information is transmitted as multisynaptic 
neural inputs through the SCN and the superior cervival ganglion (Fig. 2-9). Sympathetic 
postganglionic neurons then ascend to innervate the pineal gland (Foulkes et al. 1997). 
Circadian rhythms in the pineal gland were revealed by Quay, who noted that 5-HT levels 
in the rat pineal gland vary 10-fold in the diurnal cycle, with peak levels at midday and 
lowest levels during the night (Quay 1963). Axelrod and associates showed that this is a 
true circadian rhythm, retained during constant dark exposure but dramatically modulated 
by pulses of light (Axelrod 1974). Whereas 5-HT levels are much lower at night than day, 
melatonin concentrations display a reversed rhythm with highest concentration at night. 
At night NA release from sympathetic nerve endings is enhanced, which leads to 
stimulation of the melatonin synthesis by induction of N-acetyltransferase (NAT), mainly 
via β1-adrenergic receptors. Simultaneous activation of α1-adrenergic receptors potentiates 
the effects mediated through the β1-receptors. NAT activity is, in most circumstances, the 
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rate-limiting in melatonin biosynthesis in mammals. 5-HT is acetylated by NAT and N-
acetylserotonin is in turn methylated by the enzyme hydroxyindole-O-methyltransferase 
(HIOMT) to melatonin (Fig. 2-9) (Arendt 1997; Foulkes et al. 1997). 
 
 
Fig. 2-9. Major control mechanisms in melatonin synthesis. The suprachiasmatic nucleus 
(SCN) generates rhythmic signals, entrained to 24 h by light entering by the retina, 
relayed via the paraventricular nucleus (PVN), the hindbrain, spinal cord and superior 
cervical ganglion (SCG) to β- and α-adrenoceptors within the pineal. 
RHT=retinohypothalamic tract, NAT=N-acetyltransferase, HIOMT=hydroxyindole-O-
methyltransferase, NA=noradrenaline. Adapted from Arendt (1997) with permission from 
Springer-Verlag.  
 
In addition to the adrenergic system, the cholinergic system is also represented in the 
pineal gland (Laitinen et al. 1995). Both mAChRs and nAChRs have been identified in 
the pineal gland, α3 being the predominant nAChR subunit found (Han et al. 2000; Taylor 
et al. 1980; Wada et al. 1989; Yeh et al. 2001). The first indication for a role of 
acetylcholine in the regulation of pineal activity was provided by Zatz and Brownstein 
demonstrating that carbachol, a cholinergic agonist mimicked the effects of light on the 
circadian rhythm of NAT activity in the rat pineal gland, including the acute reduction of 
its nocturnal increase and phase shifting of the free-running rhythm (Zatz and Brownstein 
 42
1979). Further, the nAChR antagonist α-bungarotoxin blocked the effect of light on the 
nocturnal pineal NAT activity (Zatz and Brownstein 1981). Stimulation of nAChRs 
causes depolarisation and activation of L-type Ca2+ channels in rat pinealocytes (Letz et 
al. 1997), and nicotine has been shown to modulate pineal melatonin synthesis and release 
in vitro. Stankov et al. showed in vitro on pineal explants that nicotine was without effect 
on the low unstimulated melatonin levels, but had a remarkable inhibitory influence on 
NA-stimulated melatonin production (Stankov et al. 1993). Further, it was shown that 
stimulation of nAChRs triggered release of glutamate from rat pineal microvesicles and 
thereby inhibited the melatonin synthesis (Yamada et al. 1998). However, in an in vivo 
microdialysis study, nicotine infused locally in the pineal gland at night had no effect on 
the pineal melatonin concentrations in rats, whereas muscarinic agonists had a decreasing 
effect (Drijfhout et al. 1996). Thus, the data from animal studies suggest that 
acetylcholine acting through both nAChRs and mAChRs may have a modulatory role on 
pineal melatonin production. Nocturnal urinary levels of melatonin or its metabolite 6-
hydroxymelatonin sulfate have been found to be lower in smokers than in non-smokers 
(Juutilainen et al. 2000; Waldenlind et al. 1994). When daytime circulating melatonin 
levels have been measured both lower (Touitou et al. 1985) and higher (Tarquini et al. 
1994) levels have been found in smokers as compared with non-smokers. The role of 
nicotine in the relation between smoking and melatonin concentrations has not been 
clarified.  
 
There are several reports of daily variation in brain concentrations of transmitter 
monoamines and their metabolites in mice and rats. In several studies the brain tissue 
levels of DA and NA were found to reach a peak during the middle dark period, and that 
of 5-HT during the middle or latter half of the light period (Albrecht et al. 1956; Martin 
and Redfern 1997; Scheving et al. 1968). Chronic nicotine administration in the drinking 
water seemed to affect the daily rhythm of striatal DA in mice (Pietilä et al. 1995). 
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2.10. Chronic administration of nicotine to mice 
 
Humans generally consume nicotine by smoking or other means over a period measured 
in years. Therefore, it is important to also treat experimental animals for prolonged 
periods. The most frequently used methods to administer nicotine chronically have been 
intermittent subcutaneous, or intraperitoneal injections, or chronic infusion by 
subcutaneously implanted osmotic mini-pumps. Nicotine has also been administered to 
mice by intravenous infusion via the jugular vein, and orally via drinking fluids or liquid 
diets (Pietilä and Ahtee 2000). Several studies have demonstrated that rats are intolerant 
to orally administered nicotine (Le Houezec et al. 1989; Murrin et al. 1987). However, in 
chronic studies with mice there are several advantages when nicotine is administered 
orally (Pekonen et al. 1993; Rogers et al. 1998; Rowell et al. 1983; Sparks and Pauly 
1999). No surgery is required and nicotine can be delivered for long periods without 
needing to handle the animals. In oral administration the mice receive the nicotine mostly 
during the active phase of their circadian cycle, and many small peaks in nicotine 
concentrations can be achieved, consistent with the blood nicotine pharmacokinetics in 
human smokers (Benowitz et al. 1990). A disadvantage of administration via the drinking 
fluid, is that the nicotine intake of individual animals cannot be exactly controlled. 
Further, oral administration results in significantly higher steady-state levels of nicotine 
metabolites than parenteral administration (Pekonen et al. 1993; Salminen et al. 1999).  
 
Chronic administration of nicotine to mice in their drinking water has been shown to 
increase the density of [3H]-nicotine binding sites in several brain regions (Pietilä et al. 
1998; Sparks and Pauly 1999). Further, tolerance to several effects of a nicotine challenge 
has been shown to develop after a 4- or 7-week nicotine treatment (Pietilä et al. 1998; 
Pietilä et al. 1996). Thus, this method of nicotine delivery induces biochemical and 
behavioural adaptations similar to those induced in mice when using other methods of 
continuous nicotine delivery, such as intravenous or subcutaneous infusions (Marks et al. 
1991; Salminen and Ahtee 2000; Sparks and Pauly 1999).  
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3. AIMS OF THE STUDY 
 
In the present study the effects of long-term nicotine treatment and its withdrawal on 
brain monoamines and motor activity were studied using a chronic mouse model in which 
the mice are treated with nicotine orally for 7 weeks. The main aims were, firstly, to 
evaluate the effects of chronic nicotine treatment on striatal DA, and thus the role of DA 
in the mechanisms of nicotine dependence, and secondly, to clarify the effects of chronic 
nicotine treatment on circadian rhythms.  
 
The detailed aims of the present study were: 
 
To study the effects of long-term nicotine treatment and its withdrawal on locomotor 
activity of mice, and on the DA, NA and 5-HT metabolism in different brain areas (I). 
 
To study the effects of long-term nicotine treatment on the daily rhythm of motor activity 
in mice, and to study how these effects are related to daily changes in the striatal and 
accumbal DA release and metabolism, and to brain nicotine concentrations during chronic 
treatment (II). 
 
To clarify the role of nAChR activation in the effects of chronic, continuous nicotine 
treatment on accumbal DA release (III). 
 
To investigate the effects of chronic nicotine treatment on the daily rhythm of pineal 
melatonin production (IV). 
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4. MATERIALS AND METHODS 
 
4.1. Animals 
 
Male NMRI (I-III) and CBA (IV) mice were used. The mice were bred locally in the 
Laboratory Animal Center, University of Helsinki, or purchased from Harlan Netherlands 
BV. The total number of mice was 680. In most of the research NMRI mice were used, 
but CBA mice were used to study pineal melatonin, because these mice have a clear 
nocturnal pineal melatonin peak (Goto et al. 1989). Groups of 5-10 mice were housed in a 
cage. The ambient temperature was held at 20-22 °C. A 12:12-h light-dark cycle was 
imposed, with lights on from 06:00 to 18:00. Standard mice chow and tap water were 
available ad libitum. The experimental protocols were approved by the Committee for 
Animal Experiments of the Faculty of Science at the University of Helsinki or by the 
chief veterinarian of the county administrative board. All experiments were conducted 
according to the “European Convention for the Protection of Vertebrate Animals used for 
Experimental and other Scientific Purposes”. 
 
4.2. Drugs 
 
Nicotine solutions were prepared by adding (-)-nicotine base (Fluka, Buchs, Switzerland) 
to tap water. The pH of the solution was adjusted to 6.8-7.0 with 0.1 M HCl. The 
solutions were prepared every other day and stored at +4 °C. Mecamylamine 
hydrochloride (Merck, Sharp & Dohme Research Lab, Rahway, NJ, USA) was dissolved 
in saline and given in a volume of 10 ml/kg. 
 
4.3. Chronic administration of nicotine  
 
Five-week old mice (body weight 20-25 g) were divided randomly into nicotine-receiving 
and control mice. Nicotine was administered chronically in the drinking water, which was 
the sole source of fluid, as described by Pekonen et al. (Pekonen et al. 1993). In brief, the 
concentration of nicotine in the drinking water was gradually increased at 3-4-day 
intervals starting from 50 µg/ml and ending at 350 µg/ml after 3 weeks. After this it was 
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increased at 7-day intervals until 500 µg/ml was reached at 6 weeks. This gradation of 
dose was used to coax the mice to drink as steadily as possible. The control mice drank 
tap water during the entire treatment. Standard mouse chow was available ad libitum, and 
body weights were recorded once a week. The drinking fluids were changed every 
weekday, but not on weekends. The fluid intake was measured every weekend, and the 
daily nicotine intake was estimated. However, no corrections for possible spillage of 
drinking solutions were made. After 2-3 weeks the fluid intake and the weight gain of the 
nicotine-treated mice started to diminish, so that at 7 weeks the NMRI mice offered the 
500 µg/ml nicotine solution drank about 50 % and weighed 10 % less than the 
corresponding control mice, which has also been observed previously (Pekonen et al. 
1993). At 7 weeks the CBA mice drank about 30 % less and weighed 11 % less than the 
corresponding control mice. Nicotine is known to be a powerful stimulant of antidiuretic 
hormone release, and thus reduces the output of urine (Burn et al. 1945). Since small 
rodents maintain their fluid balance very effectively, it appears that the mice reduced their 
fluid intake to compensate for the reduced fluid output. The hypodipsia induced by the 
higher nicotine concentrations could also be partially due to the bitter taste of the solution 
offered. Nonetheless, the nicotine intake from the third week onward was estimated to be 
about 60-65 mg/kg/day for the NMRI mice and 50-55 mg/kg/day for the CBA mice. After 
7 weeks of nicotine administration some of the mice were withdrawn from the chronic 
nicotine regimen by replacing the nicotine solution with tap water (Study I).  
 
4.4. Measurement of motor activity  
 
Motor activity was measured in Study I and II. In study I the animals were placed singly 
in plastic cages (22 x 38 x 15 cm), which were covered with perforated plastic lids and 
that was then placed on top of a sensor containing 40 photocells. A 25 W lamp was placed 
at a distance of 100 cm, and interruptions of light beams to the photocells as a result of 
horizontal movement of the animals were registered by a computer. Activity was 
measured for a 60 min period in the forenoon. The mice were introduced to the test 
situation at about 24 h before the experiment by placing them in the test cages for a 60 
min period. In study II the mice were placed in the same type of cages but in groups of 
three. The bottoms of the cages were covered with new sawdust and food was scattered 
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on the floor. The cages were placed in activity monitors (MED Associates’ open field 
activity monitor, St Albans, USA), and the animals were allowed to habituate in the cages 
for 2-3 h before the activity monitoring began. The activity was monitored continuously 
over a 24 h period beginning at 4-5 h after the light onset. Infrared photo-beam 
interruptions were registered and analyzed by the software of the activity monitor at 
counting intervals of 30 min. Nicotine solution or tap water (control mice) was 
continuously available throughout the experiment. 
 
4.5. Dissection of brain  
 
The mice were killed by decapitation, and then their brains were immediately removed 
from the skull and placed on a chilled glass plate. The optic nerves, olfactory bulbs and 
cerebellum were removed and discarded. As subsequent parts were removed, they were 
frozen immediately on dry ice. The hypothalamus was pinched off. The cortical 
hemispheres were spread apart and separated by cutting the corpus callosum, and the 
hippocampi were peeled away. The medial borders of the striata were freed, and the 
striata (caudate putamen + nucleus accumbens) removed without the underlying cortex. 
Finally the cortex was separated from the rest of the brain. The parts were weighed (mean 
weights: hypothalamus 15 mg, striata 25 mg, cortex 190 mg) and then stored at -80 °C 
until assayed.  
 
4.6. Measurement of monoamines and their metabolites from tissue samples 
 
The concentrations of DA, DOPAC, 5-HT and 5-HIAA in striatal tissues and NA, 
MOPEG, 5-HT and 5-HIAA in hypothalamic and cortical tissues were measured by high-
performance liquid chromatography (HPLC) with electrochemical detection. The 
measurements were made following a Sephadex G-10 gel chromatographic clean-up of 
samples, as described by Haikala (Haikala 1987). The system for determining DA and NA 
consisted of an ESA Coulochem 5100A detector equipped with a model 5014 analytical 
cell, and a Pharmacia LKB model 2150 pump having an SSI model 20-0225 pulse 
damper. The column (Spherisorb ODS2 5 µm, 25 cm, 4.6 mm i.d.) was kept at +40 °C 
with a Bio-rad column heater. The mobile phase used consisted of 0.1 M NaH2PO4 
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buffer, pH 2.4 (adjusted with citric acid), 0.6-0.8 mM octane sulfonic acid, 10-15 % 
methanol and 1.2 mM EDTA. The detector was set at +780 mV. The detection limit of the 
assay was 0.15 pg/µl (1 fmol/µl) for DA. The system for determining DOPAC, HVA, 5-
HT, 5-HIAA and MOPEG consisted of an ESA Coulochem II detector equipped with a 
model 5014 analytical cell, a Beckman model 110B pump having an SSI model LP-21 
pulse damper and Spherisorb ODS2 5 µm (25 cm, 4.6 mm i.d.) column. The mobile phase 
used consisted of 0.2 M Na2HPO4 buffer, pH 4.8 (adjusted with citric acid), 12-15 % 
methanol and 1.2 mM EDTA. The detector was set at +380mV. Monoamine and 
metabolite values were calculated as micrograms per gram (µg/g) wet weight of tissue. 
 
4.7. Measurement of brain nicotine concentrations 
 
For the measurements of brain nicotine concentrations some of the mice were from day 
28 of nicotine administration onwards maintained on an altered light-dark cycle with 
lights on from midnight to noon. On the 50th day of nicotine administration mice were 
killed by decapitation at various times. The times of sacrifice were at 5 or 9 hours after 
the light onset or at 3 or 11 hours after the light offset. After removing the cerebellum, the 
brain tissue was weighed and homogenised in 3.0 ml/g 0.1 N HCl. The homogenates were 
stored at -80°C until assayed. Before use all laboratory equipment was carefully rinsed 
with ethanol and kept in an oven at +40-100 ˚C for at least 12 h in order to remove 
nicotine contamination. Nicotine concentrations were measured by a gas 
chromatographic-mass spectrometric (GC-MS) method using selected ion monitoring 
(SIM) as earlier described (Leikola-Pelho et al. 1990) with slight modifications (Seppä et 
al. 2000). Analyses were made on a Hewlett-Packard 5970 quadropole MS coupled to a 
Hewlett-Packard 5890 GC having an NB-54 fused silica column (15m). Fragment ions of 
m/z 84 (nicotine) and 129 (quinoline, internal standard) were used for single ion 
monitoring. The concentrations of nicotine were calculated as nanograms per gram (ng/g) 
brain tissue. Sensitivity of this assay was 10 ng/ml and the correlation coefficient of the 
standard samples between 25 and 300 ng/ml was 0.989. Coefficient of variation 
(reproducibility) of the method was 4.8 % (n=3) for nicotine at the concentration of 100 
ng/ml homogenate.  
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4.8. In vivo microdialysis  
 
After 6-week nicotine treatment mice were implanted with guide cannulas (CMA/7, 
CMA/Microdialysis, Stockholm, Sweden) under chloral hydrate anaesthesia (450 mg/kg 
i.p.). The mice were also treated with buprenorphine (0.6 mg/kg s.c.) to relieve pain 
during surgery. The coordinates for the guide cannulas were calculated relative to bregma 
and were aimed at the point above the nucleus accumbens (A/P = + 1.4, L/M = + 0.9, D/V 
= - 3.8) according to the mouse brain atlas (Franklin and Paxinos 1997). The cannula was 
fastened to the skull with dental cement (Aqualox, Voco, Germany) and two stainless 
steel screws. After the surgery the mice were placed into individual cages (30 x 30 x 40 
cm) and allowed to recover for at least 5 days before the experiment was begun. The mice 
were kept in their same cages throughout the rest of the experiment. At about 16:00 on the 
day before the experiment, a microdialysis probe (CMA/7, CMA/Microdialysis, 
Stockholm, Sweden; 1.0 mm membrane, o.d. 0.24 mm) was inserted into the guide 
cannula and infused with a modified Ringer solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 
mM KCl, 1.0 mM MgCl2 and 0.04 mM ascorbic acid) at a flow rate of 0.5 µl/min. At 
about 8:00 on the morning of the experimental day the flow rate of the infusion was 
increased to 2 µl/min. After a stabilization period of 2 hours the collection of actual 
microdialysis samples was begun with a 40 µl sample taken every 20 min. The system 
used to determine the concentrations of DA, DOPAC, HVA and 5-HIAA in the dialysates 
consisted of an ESA Coulochem II detector equipped with a model 5014B microdialysis 
cell, a Pharmacia LKB model 2248 HPLC pump and a SSI model LP-21 pulse damper. 
The column (Spherisorb ODS2, 3 µm, 10 cm, 4.6 mm i.d.) was kept at +40 °C with a 
column heater (Croco-Cil, France). The mobile phase used consisted of 0.1 M NaH2PO4 
buffer, pH 4.0 (adjusted with citric acid), 0.6-0.8 mM octane sulfonic acid, 12-15 % 
methanol and 1.2 mM EDTA. The flow rate of the mobile phase was 1.0 ml/min. Thirty-
five µl of the dialysis sample was injected onto the column with a CMA/200 auto-injector 
(CMA, Stockholm, Sweden). DA was reduced with an amperometric detector (potential -
100 mV) after being oxidized with a coulometric detector (+300 mV), and DOPAC, HVA 
and 5-HIAA were oxidized with the coulometric detector. The detection limit of the assay 
was 0.1 fmol/µl (0.015 pg/µl) for DA. The chromatogram was processed with a Hitachi 
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D-2000 chromato-integrator (E. Merck, Darmstadt, Germany). The average concentration 
of the first four stable samples was considered the baseline and defined as 100 %. The 
results of samples, collected after the acute drug injection, were then presented as 
percentage of the baseline. Nicotine solution or tap water (control mice) was continuously 
available throughout the experiment. After completion of the experiment, the positions of 
the microdialysis probes were determined histologically from brain sections prepared post 
mortem. Only results derived from animals with correctly positioned probes were 
considered valid. 
 
4.9. Measurement of pineal melatonin content  
 
For the measurements of nocturnal pineal melatonin concentrations the mice were from 
the first week of nicotine administration onwards maintained on an altered light-dark 
cycle with lights on from midnight to noon. Pineal glands from both nicotine-treated and 
control mice were collected at 5 h after the light onset and at 1, 3, 5, 7, 9, 10 or 11 h after 
the light offset. All experiments in the dark phase were performed under a dim red light. 
The mice were decapitated, and the skull caps with attached pineal glands were cut away 
and immediately placed on dry ice. The frozen pineal glands were removed from the skull 
caps and stored at -20 °C until homogenisation. Melatonin was measured in the 
supernatant of pineal homogenates by the radioimmunological method (Vakkuri et al. 
1984) described previously in detail by Laakso et al. (Laakso et al. 1988) for rats. The 
method was modified for the mice pineal gland by reducing the volume of phosphate 
buffer used in the homogenization to 0.4 ml per gland. The intra-assay variability 
calculated from the duplicate measurements was 7 %. The interassay variability of 19 
assays during 9 months was 8-13 %, depending on the concentration. Non-specific 
binding was 5-6 %, and the detection limit (2 SD:s) < 1.95 pg/tube (5 pg/gland). 
 
4.10. Statistical analysis 
 
The data from the locomotor activity experiments were analysed by a two-way analysis of 
variance (ANOVA) followed by multiple comparisons using contrast analysis (I). Data 
from the 24-h continuous motor activity measurements were analysed by a one-way 
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ANOVA for repeated measures, followed by the Tukey-Kramer post hoc test (II). The 
concentrations of monoamines and their metabolites in tissue samples were compared by 
one-way ANOVA followed by the Tukey Compromise post hoc test (I), Student’s t-test 
(II) or two-way ANOVA followed by multiple comparisons using contrast analysis (IV). 
The data from microdialysis studies were subjected to one-way ANOVA for repeated 
measures. When appropriate, multiple comparisons were conducted using Student-
Newman-Keuls post hoc test (III). The absolute basal values of DA and metabolites in 
dialysates were compared using Student’s t-test (II, III). The pineal melatonin 
concentrations were compared by two-way ANOVA followed by multiple comparisons 
using contrast analysis (IV). P-values lower than 0.05 were considered to be significant. 
 
 
5. RESULTS 
 
5.1. Cerebral nicotine concentration during chronic nicotine treatment (II) 
 
The brain nicotine concentrations measured at four time points on the 50th day of nicotine 
administration in the drinking water are shown in Table 5-1. The highest concentration 
was found at 11 h after the light offset and the lowest concentration at 9 h after the light 
onset. 
 
Table 5-1. Brain concentrations (mean ± SEM) of nicotine in NMRI mice at four time 
points on the 50th day with nicotine in the drinking water (n = 11-13 in all groups). 
 
Time (h after light 
onset/offset) 
 
5 
 
9 
 
3 
 
11 
Nicotine (ng/g) 299 ± 49 243 ± 35 307 ± 60 329 ± 53 
Table shows data from Study II. The values given (ng/g) are means ± SEM from 11-13 
mice maintained on a 12:12-h light/dark cycle. The shadowed area represents the dark 
period. 
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5.2. Effects of chronic nicotine treatment and its withdrawal on motor activity (I, 
II) 
 
The effects of 7-week nicotine administration and its withdrawal on the locomotor 
activity of NMRI mice are shown in Fig. 5-1. The locomotor activity was increased 
during the chronic treatment. 12-14 h after withdrawal from nicotine the locomotor 
activity of the mice was lower than during the chronic nicotine treatment. The activity of 
mice withdrawn for 12-14 h was also slightly lower than that of the control mice, but this 
difference was not statistically significant. Further, the activity of mice withdrawn for 23-
25 h did not differ from that of the control mice or the mice drinking nicotine-containing 
solution. 
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Fig. 5-1. The locomotor activity of NMRI mice on the 50th day with nicotine in the 
drinking water and after 12-14 or 23-25 h withdrawal. Control mice were drinking tap 
water throughout the experiments. The locomotor activity was measured for a 60 min 
period in the forenoon (3-6 h after the light onset). *P<0.05, **P<0.01 (n = 6-8 in all 
groups) (Study I). 
 
In study II, gross motor activity of groups of three mice was measured over a 24 h period 
on the 50th day of nicotine administration. As shown in Fig. 5-2, the daily rhythmicity of 
motor activity was similar in nicotine-treated and in control mice. A longer-lasting 
activity peak occurred after the lights were switched off, and a smaller peak occurred after 
the lights were switched on. In the beginning of the active periods the control mice and 
the nicotine-treated mice were about equally active, but in both periods the nicotine-
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treated mice remained active for about two hours longer than the control mice. Thus, the 
mice drinking nicotine solution were significantly more active than the control mice in the 
three consecutive 1.5-h intervals from 1.5 to 6 h after the light onset and in the two 
consecutive 1.5-h intervals from 6 to 9 h after the light offset. 
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Fig. 5-2. Motor activity of nicotine-treated and control NMRI mice over 24 h on the 50th 
day with nicotine in the drinking water. *P<0.05, **P<0.01 versus control mice drinking 
tap water, (n = 7 groups of 3 mice in both treatment groups). The mice were kept on a 
12:12-h light-dark cycle. The black bar corresponds to the dark period. The scale of the 
marked horizontal axis is divided at 1.5-h intervals (II).  
 
5.3. Effects of chronic nicotine treatment and its withdrawal on brain monoamines 
in NMRI mice (I, II and previously unpublished data) 
 
The effects of chronic nicotine treatment and its withdrawal on the striatal concentrations 
of DA, 5-HT and their metabolites are summarised in Table 5-2. In study I the tissue 
samples were collected at 5 h after the light onset on the 50th day of nicotine 
administration, or at 12-14 or 23-25 h after withdrawal of nicotine. In a separate 
experiment (Study II) the samples were obtained at 8 h after the light offset on the 50th 
day of nicotine administration. The striatal HVA and 5-HIAA levels were significantly 
increased in the nicotine-treated mice at both time points measured on the 50th day of 
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nicotine administration. The striatal DOPAC concentration was significantly increased in 
the nicotine-treated mice at 5 h after the light onset and tended to also be increased at 8 h 
after the light offset. The striatal DA and 5-HT levels were significantly elevated in the 
nicotine-treated mice at 8 h after the light offset. At 12-14 and 23-25 h after nicotine 
withdrawal the striatal concentrations of DA, 5-HT and their metabolites did not differ 
from that of the controls. Thus, the effects of the chronic treatment on the striatal DA and 
5-HT metabolism disappeared during withdrawal. 
 
Table 5-2. Summary of the effects of chronic nicotine treatment and its withdrawal on the 
striatal concentrations of DA, 5-HT and their metabolites in NMRI mice. 
 
50th day of nicotine 
treatment 
DA DOPAC HVA 5-HT 5-HIAA 
at 5 h after light onset - ↑↑ ↑↑ - ↑↑↑ 
at 8 h after light offset ↑ + ↑↑ ↑↑ ↑↑ 
Withdrawal  
for 12-14 h - - - - - 
for 23-25 h - - - - - 
Table summarises results from Fig. 2 and 4 in Study I, Fig. 2 in study II and previously 
unpublished data (at 8 h after the light offset the striatal concentrations, µg/g, mean ± 
SEM, were in control mice 5-HT: 0.41 ± 0.01 and 5-HIAA: 0.28 ± 0.01, and in nicotine-
treated mice 5-HT: 0.49 ± 0.03 and 5-HIAA 0.37 ± 0.02, respectively). The arrows show 
the significant changes (P<0.05) induced by chronic nicotine treatment or its withdrawal 
as compared with control mice drinking tap water. ↑ increase by 10-20 %, ↑↑ increase by 
20-30 %, ↑↑↑ increase by 30-40 %, + tendency to increase (P=0.06). A dash (-) indicates 
no significant change.  
 
The effects of chronic nicotine treatment and its withdrawal on the hypothalamic and 
cortical concentrations of NA, 5-HT and their metabolites are summarised in Table 5-3. 
The tissue samples were collected at the periods outlined in the previous paragraph. The 
NA concentrations were increased in the nicotine-treated mice in both brain areas at 5 h 
after the light onset. The hypothalamic MOPEG concentration was increased in nicotine-
treated mice at 8 h after the light offset, and the hypothalamic 5-HIAA at 5 h after the 
light onset. However, the cortical 5-HIAA concentration was increased in the nicotine-
treated mice at 8 h after the light offset. At 12-14 h after withdrawal the hypothalamic 
concentrations of NA, MOPEG and 5-HIAA were all higher in the nicotine-treated mice 
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than in the control mice, but at 23-25 h after withdrawal only the hypothalamic NA was 
still slightly increased. 
 
Table 5-3. Summary of the effects of chronic nicotine treatment and its withdrawal on the 
hypothalamic and cortical concentrations of NA, 5-HT and their metabolites in NMRI 
mice. 
 
Hypothalamus Cortex 50th day of 
nicotine 
treatment 
NA MOPEG 5-HT 5-HIAA NA MOPEG 5-HT 5-HIAA 
at 5 h after 
light onset ↑↑ - - ↑↑ ↑ - - - 
at 8 h after 
light offset - ↑ - - - ND - ↑ 
Withdrawal  
for 12-14 h  ↑ ↑ - ↑ - - - - 
for 23-25 h  ↑ - - - - - - - 
Table summarises results from Fig. 3 and 4 in study I and previously unpublished data (at 
8 h after the light offset the hypothalamic concentrations, µg/g, mean ± SEM, were in 
control mice NA: 1.93 ± 0.07, MOPEG: 0.122 ± 0.005, 5-HT: 1.69 ± 0.09 and 5-HIAA: 
0.57 ± 0.02, and in nicotine-treated mice NA: 1.92 ± 0.05, MOPEG: 0.139 ±0.005, 5-HT: 
1.66 ± 0.07 and 5-HIAA: 0.61 ± 0.01; the cortical concentrations, µg/g, mean ± SEM, 
were in control mice NA: 0.21 ± 0.01, 5-HT: 0.79 ± 0.03 and 5-HIAA: 0.20 ± 0.01, and in 
nicotine-treated mice NA: 0.21 ± 0.01, 5-HT: 0.84 ± 0.04 and 5-HIAA: 0.23 ± 0.01, 
respectively). The arrows show the significant changes (P<0.05) induced by chronic 
nicotine treatment. ↑ increase by 10-20 %, ↑↑ increase by 20-30 %. A dash (-) indicates 
no significant change. ND = not determined.  
 
In order to study the effects of chronic nicotine treatment on the daily rhythm of 
hypothalamic and cortical 5-HT metabolism in NMRI mice, the cortical and hypothalamic 
concentrations of 5-HT and 5-HIAA were measured at four time points on the 50th day of 
nicotine consumption. The results are shown in Table 5-4. Two-way ANOVA revealed no 
significant time effects. Thus, no clear time-related fluctuations were observed in the 5-
HT and 5-HIAA concentrations of either control or nicotine-treated mice. However, 
ANOVA revealed a significant effect of treatment on the hypothalamic 5-HT and 5-HIAA 
concentrations and on the cortical 5-HIAA concentrations. Multiple comparisons showed 
that the 5-HIAA concentrations were significantly increased in nicotine-treated mice in 
both brain areas at 5 and 9 h after the light onset. Thus, the hypothalamic 5-HT 
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metabolism was significantly increased only in the light period during the chronic 
nicotine treatment. However, the hypothalamic concentration of 5-HT was significantly 
increased in the nicotine-treated mice both at 5 h after the light onset and at 3 h after the 
light offset.  
 
Table 5-4. Hypothalamic and cortical concentrations of 5-HT and 5-HIAA in NMRI mice 
at four time points on the 50th day of nicotine or tap water (control) administration.  
 
5-HT 
 
5-HIAA Time (hours 
after light 
onset/offset) Hypothalamus 
 Control Nicotine Control Nicotine 
5  1.49 ± 0.09 1.93 ± 0.12** 0.59 ± 0.03 0.69 ± 0.02** 
9 1.82 ± 0.14 1.95 ± 0.13 0.63 ± 0.03 0.70 ± 0.03* 
3 1.59 ± 0.06 2.013± 0.13** 0.65 ± 0.02 0.67 ± 0.02 
11 1.89 ± 0.12 2.00 ± 0.12 0.65 ± 0.02 0.63 ± 0.02 
 Cortex 
5 0.56± 0.03 0.61 ± 0.03 0.17 ± 0.01 0.20 ± 0.01* 
9 0.55 ± 0.03 0.56 ± 0.03 0.17 ± 0.01 0.20 ± 0.01* 
3 0.55 ± 0.02 0.56 ± 0.02 0.18± 0.01 0.18 ± 0.01 
11 0.62 ± 0.03 0.61 ± 0.04  0.17 ± 0.01 0.17 ± 0.01 
Table shows previously unpublished data. The values are means (µg/g) ± SEM (n = 18-20 
in all groups). *P<0.05, **P<0.01 vs. control mice. The mice were kept on a 12:12-h 
light-dark cycle. The shadowed area represents the dark period. 
 
5.4. Effects of chronic nicotine treatment and mecamylamine on accumbal 
extracellular concentrations of dopamine and its metabolites (II, III) 
 
Microdialysis experiments were performed in the forenoon (4-7 h after the light onset) of 
the 50th day of nicotine administration. Increased steady state concentrations of DA in the 
accumbal dialysates were observed in the nicotine-treated mice (Table 5-5). A significant 
increase in the accumbal DOPAC concentration was also observed in study II, but this 
was not observed in study III. The concentrations of HVA and 5-HIAA in the dialysates 
were not affected by the nicotine treatment. 
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Table 5-5. The steady state concentrations of DA, DOPAC, HVA and 5-HIAA in nucleus 
accumbens dialysates of NMRI mice on the 50th day of chronic nicotine or tap water 
(control) treatment.  
 
Treatment DA  
fmol/40 µl 
DOPAC 
pmol/40µl 
HVA 
pmol/40 µl 
5-HIAA 
pmol/40 µl 
Study II 
    
Tap water 9.51 ± 1.33  1.34 ± 0.18 1.70 ± 0.21  - 
Nicotine  21.92 ± 3.68** 2.49 ± 0.33** 2.26 ± 0.26 - 
Study III 
    
Tap water 15.94 ± 2.10 2.74 ± 0.39 2.54 ± 0.30 0.75 ± 0.09 
Nicotine  27.43 ± 3.71* 2.45 ± 0.32 2.23 ± 0.27 0.69 ± 0.09 
Table shows data from study II and III, *P<0.05, **P<0.01 vs. control mice. Four 
consecutive 40 µl dialysate samples were collected at 20 min intervals from each animal. 
The concentrations as fmol (DA) or pmol (DOPAC, HVA 5-HIAA) were averaged. The 
values given are means ± SEM of the data obtained from 12 (Study II) or 16-20 (Study 
III) mice. 
 
Mecamylamine (2 mg/kg s.c.) given during the chronic treatment decreased the accumbal 
DA output in the nicotine-treated mice (Fig. 5-3). The maximum reduction from the 
baseline level was 32 %. It is to be noted that the baseline DA levels in nicotine-treated 
mice were about double those of the control mice though. Thus, mecamylamine did not 
decrease the extracellular accumbal DA levels in the nicotine-treated mice to below those 
found in control mice, but it did bring the increased DA levels back to control levels. 
Mecamylamine’s effect on the accumbal DA output in the control mice did not differ 
from that of a saline injection; a small increase above the baseline was seen after both 
acute treatments, probably due to stress resulting from handling and injection. 
Mecamylamine also induced a slight decrease in the HVA output in the nicotine-treated 
mice but it was not statistically significant. The DOPAC and 5-HIAA outputs were not 
significantly affected by mecamylamine in either the nicotine-treated or control mice. 
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Fig. 5-3. Effects of mecamylamine (2 mg/kg s.c.) and saline (s.c.) on the accumbal 
extracellular concentrations of DA, DOPAC, HVA and 5-HIAA in nicotine-treated and 
control NMRI mice (n = 8-11 in all groups), with the arrow indicating the time of 
injection. All values are presented as percentages of the baseline (III). 
 
5.5. Effects of chronic nicotine treatment on daily rhythms of pineal melatonin and 
brain transmitter monoamines in CBA mice (IV) 
 
As shown in Fig. 5-4, the peak levels of pineal melatonin were reached 10 h after the light 
offset in both the control mice and nicotine-treated mice. Thus, chronic nicotine treatment 
did not affect the circadian rhythm of pineal melatonin production. However, the pineal 
melatonin levels were significantly lower in the nicotine-treated mice than in the control 
mice at 9 and 11 h after the light offset. In the light period (data not shown), and at the 
first three time points measured in the dark period, the pineal melatonin levels in control 
and nicotine-treated mice touched the detection limit. At 11 h after the light offset, a 
greater part of mice in the nicotine group (5/6 or 83 %) than in the control group (2/5 or 
40 %) were found to have a low melatonin content (< 10 pg/gland, i.e. similar to the 
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levels in the light period and in the beginning of the dark period). Thus, it seems that the 
nocturnal period of high melatonin content in the pineal gland was slightly shorter in the 
nicotine-treated mice. 
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Fig. 5-4. The nocturnal pineal melatonin content in CBA mice on the 50th day of chronic 
nicotine administration. Control mice were drinking tap water (n = 4-7 in all groups). 
*P<0.05, **P<0.01 vs. control mice. The mice were kept on a 12:12-h light-dark cycle 
(Study IV).  
 
In study IV the concentrations of transmitter monoamines and their metabolites were 
measured in striatal, hypothalamic and cortical tissues of CBA mice at three time points 
(at 4 h after the light onset and at 2 and 8 h after the light offset) on the 50th day of 
nicotine administration The effects of the chronic nicotine treatment on the striatal 
concentrations of DA, DOPAC, HVA, 5-HT and 5-HIAA are summarised in Table 5-6. 
The striatal concentrations of DOPAC, HVA and 5-HIAA, but not that of 5-HT, were 
increased in the nicotine-treated mice (two-way ANOVA). Multiple comparisons showed 
that the striatal DA and HVA concentrations were significantly higher in the nicotine-
treated mice than in the controls at 8 h after the light offset. A significant daily fluctuation 
was found in the striatal HVA concentration in the control mice, in which the 
concentration was significantly higher at 2 h than at 8 h after the light offset. However, in 
the nicotine-treated mice the daily fluctuation in striatal HVA was abolished.  
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Table 5-6. Summary of the effects of chronic nicotine treatment on striatal concentrations 
of DA, 5-HT and their metabolites in CBA mice 
 
Time (hours after 
light onset/offset) DA DOPAC HVA 5-HT 5-HIAA 
4 3 % 7 % 11 %+ 0 % 3 % 
2 2 % 11 % 9 % -3 % 8 % 
8 15 %* 10 % 21 %** 21 % 17 % 
Table summarises results from Fig. 2 in study IV. The values indicate the percent 
increase/decrease in concentration induced by chronic nicotine treatment as compared 
with corresponding controls, *P<0.05, **P<0.01, +P<0.07. The mice were kept on a 
12:12-h light-dark cycle. The shadowed area represents the dark period. 
 
The effects of chronic nicotine treatment on the hypothalamic and cortical concentrations 
of NA, 5-HT and their metabolites are summarised in Table 5-7. The concentrations of 
NA, MOPEG and 5-HIAA in the hypothalamus, and the concentration of MOPEG in the 
cortex, were increased in the nicotine-treated mice (two-way ANOVA). Multiple 
comparisons showed that the hypothalamic concentrations of NA and MOPEG were 
significantly higher in the nicotine-treated mice than in the control mice at 4 h after the 
light onset and at 8 h after the light offset. At 4 h after the light onset the hypothalamic 5-
HIAA level was significantly higher in the nicotine-treated mice than in the controls. At 2 
and 8 h after the light offset the cortical MOPEG concentrations were significantly higher 
in the nicotine-treated mice than in the control mice.  
 
Table 5-7. Summary of the effects of chronic nicotine treatment on hypothalamic and 
cortical NA, 5-HT and their metabolites in CBA mice. 
 
Hypothalamus Cortex Time 
(hours after 
light 
onset/offset) NA MOPEG 5-HT 5-HIAA NA MOPEG 5-HT 5-HIAA 
4 14 %*** 17 %* 4 % 11 %* 6 % 5 % 0 % 9 % 
2 6 % 13 % 1 % 3 % -8 % 13 %** -3 % 4 % 
8 9 %* 15 %* 5 % 6 % 7 % 10 %** 0 % 3 % 
Table summarises results from Fig. 3 and 4 in study IV. The values indicate the percent 
increase/decrease in concentration induced by chronic nicotine treatment as compared 
with corresponding controls. *P<0.05, **P<0.01, ***P<0.001. The mice were kept on a 
12:12-h light-dark cycle. The shadowed area represents the dark period. 
 
 61
6. DISCUSSION 
 
6.1. Brain nicotine concentrations in mice 
 
In previous studies using the nicotine administration method, which was used in the 
present study, the highest plasma nicotine concentration in mice was observed at late 
night-time (114 ng/ml at 11 h after the light offset) when it was more than double the 
concentrations found at other time points studied (54 ng/ml, 48 ng/ml and 33 ng/ml at 5 
and 9 h after the light onset and at 3 h after the light offset, respectively) (Pietilä et al. 
1995). Blood or plasma nicotine concentrations sampled in the afternoon in smokers 
range from 10-50 ng/ml (Benowitz et al. 1990). Thus, nicotine levels similar to or above 
those in smokers are achieved by this administration method. In the present study, the 
daily fluctuations in cerebral nicotine concentrations in the mice were found to be rather 
small as compared to the daily fluctuations in plasma concentrations found previously 
(Pietilä et al. 1995). This can be explained by the longer half-life of nicotine in the brain 
than in the blood (Sastry et al. 1995). There were, however, large individual differences in 
brain nicotine concentrations measured at the same time point, suggesting that the daily 
fluctuations in nicotine concentrations in individual subjects might be significant. In 
accordance with previous measurements of plasma concentrations, the highest brain 
nicotine concentration was found in the latter part of the dark period, indicating that the 
mice consumed most of their daily fluid during their active period. In agreement with 
previous studies with both mice and rats (Benowitz et al. 1990; Ghosheh et al. 2001; 
Mansner and Mattila 1977; Rowell and Li 1997) the nicotine concentrations in the brain 
exceeded several-fold those in plasma. 
 
The measurements discussed above were carried out in NMRI mice. In study IV, CBA 
mice were used. The daily fluid intake, and thus, the estimated daily nicotine intake of the 
CBA mice was slightly smaller than that of the NMRI mice. The plasma nicotine 
concentration on the 50th day of nicotine administration at 5 h after the light onset was 41 
ng/ml (n = 3) in the CBA mice, which is slightly less than that measured in NMRI mice 
(54 ng/ml). 
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6.2. Motor activity and striatal and accumbal dopamine in NMRI mice 
 
The present results represent the first demonstration of significant nicotine-induced 
locomotor stimulation in NMRI mice. Increased motor activity was previously observed 
in C57Bl/6 mice on the first three days of nicotine administration in the drinking water 
(Sparks and Pauly 1999). In the present study, nicotine stimulated motor activity on the 
50th day of nicotine treatment, suggesting that tolerance to this effect does not develop in 
mice with this method of nicotine administration. Thus, the effects of nicotine intake via 
the drinking fluid on locomotor activity are in line with results from rat studies, which 
utilized intermittent nicotine treatment (Clarke and Kumar 1983), but are in contrast to 
studies in which continuous nicotine infusion induced tolerance to the stimulant effect of 
nicotine (Benwell et al. 1995; Morley and Garner 1990). The increased motor activity in 
the nicotine-treated mice of our study might reflect behavioural sensitization similar to 
that found in rats subjected to repeated intermittent nicotine treatments (Benwell and 
Balfour 1992; Nisell et al. 1996). However, it should be noted that, at 24 h after 
withdrawal of a 7-week treatment of nicotine via the drinking water, a subcutaneous 
injection of a small dose of nicotine (0.5 mg/kg) induced no stimulation of locomotor 
activity in the mice, although the mice were tolerant to the locomotor depressant effect 
(Pietilä et al. 1998). In rats, however, clear sensitization of the locomotor stimulant effect 
of a nicotine bolus was observed at the same time point following withdrawal of a 14-day 
continuous nicotine infusion (Benwell et al. 1995).  
 
Most studies of nicotine’s effect on motor activity have been performed during the light 
phase of the day. Under a light-dark cycle the activity rhythm of laboratory animals is 
entrained to a 24-h period by light cues, and their active phases occur mainly during the 
dark phase. Despite this typical nocturnal profile, mouse strains exhibit different 
distributions of their activity (Kopp 2001). In study II the motor activity was monitored 
continuously over a 24 h period in order to study the daily activity rhythms of both 
nicotine-treated and control mice. The daily pattern of activity observed in the NMRI 
mice was similar to the bimodal circadian pattern observed in former studies of some 
other mouse strains (Kopp 2001; Weinert and Waterhouse 1999). A major activity peak 
occurred immediately after the lights were switched off, and a minor peak occurred after 
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the lights were switched on. Interestingly, the periods when the nicotine-treated mice 
were more active than the control mice occurred immediately following the activity 
peaks, as prolongation of the natural activity peaks. Thus, the motor activity was 
enhanced in the nicotine-treated mice at 2-6 h after the light onset, and at 6-9 h after the 
light offset, suggesting that the mice consumed enough nicotine during their active 
periods to stimulate motor activity. However, the overall circadian pattern of activity was 
not altered by the chronic treatment. This finding is in agreement with previous studies of 
rats, which showed that chronic nicotine treatment did not affect the circadian patterns of 
ambulatory activity (Kita et al. 1985; Morley and Garner 1990). However, in previous 
studies, in which nicotine was administered by subcutaneous infusion, increased motor 
activity was exhibited by the nicotine-treated rats only during the light period (Morley and 
Garner 1990). On the other hand, studies in which nicotine was administered via the 
drinking water, observed increased motor activity in rats and mice only during the dark 
period (Kita et al. 1985; Sparks and Pauly 1999). It is possible that the NMRI mice, which 
have a clear activity peak in the morning, consumed enough nicotine also in the beginning 
of the light period to stimulate day-time motor activity. There are also some previous 
findings showing that the stimulating effect of psychostimulants varies during the 
circadian cycle. For example, the highest effect of methamphetamine on ambulatory 
activity in mice was observed when it had been administered at 9 h after the light offset, 
and the lowest activity counts were found after its administration at 9 h after the light 
onset (Kuribara and Tadokoro 1982). This circadian variation in susceptibility was 
maintained after repeated administrations (Kuribara and Tadokoro 1984).  
 
In this study, the striatal concentrations of DOPAC and HVA were increased in the NMRI 
mice at 5 after the light onset on the 50th day of nicotine administration, which is 
consistent with the previous study of Pietilä et al. (Pietilä et al. 1995). Further, in the 
present study significant increases of striatal DA and HVA concentrations were found at 8 
h after the light offset, at which time the DOPAC concentration also tended to be 
increased. In previous studies no changes in the striatal concentrations of DA and its 
metabolites were found at 3 or 11 h after the light offset or at 9 h after the light onset 
(Pietilä et al. 1995). At those time points no differences in activity levels between 
nicotine-treated and control mice were found in this study. Thus, the striatal DA 
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metabolism and the motor activity of the nicotine-treated mice were both elevated at 5 h 
after the light onset and at 8 h after the light offset, suggesting that the mice consume 
enough nicotine during their active periods to enhance DA release and to stimulate motor 
activity. The findings suggest that the cerebral dopaminergic systems are important in the 
mediation of nicotine-induced hyperactivity in mice. The striatal 5-HT metabolism was 
also found to be elevated in the nicotine-treated mice at the same time points. Indeed, 
there is evidence for 5-HT-DA interactions in the control of motor and reward-related 
behaviour (Broderick and Phelix 1997; Sasaki-Adams and Kelley 2001).  
 
The brain area dissected as striatum for the post mortem determinations of DA and its 
metabolites contained the dorsal (caudate-putamen) as well as the ventral striatum 
(nucleus accumbens). As the stimulant action of nicotine and other psychostimulants on 
motor activity has been linked to enhanced activity in the mesolimbic dopaminergic 
pathway projecting to the nucleus accumbens (Clarke et al. 1988; Kelly et al. 1975), the 
extracellular concentrations of DA and its metabolites in this area were estimated by in 
vivo microdialysis in freely moving mice. The experiments were carried out at 4-7 h after 
the light onset on the 50th day of nicotine administration. The steady-state concentrations 
of DA, and in study II, also that of DOPAC, in the accumbal dialysates, were higher in the 
nicotine-treated mice than in the control mice. The effects of chronic nicotine 
administration on the accumbal DA output have not been previously studied in mice. The 
present findings are in agreement with a rat study showing elevated accumbal steady-state 
DA output on the 9th day of continuous nicotine infusion (Carboni et al. 2000). Acute 
nicotine has been shown to increase the accumbal DA output in anaesthetised mice 
(Picciotto et al. 1998), and the stimulating effect of acute nicotine on accumbal DA 
release in rats has been well described (Imperato et al. 1986; Nisell et al. 1994; Seppä et 
al. 2000). In the present study, the nAChR antagonist mecamylamine decreased the 
accumbal extracellular DA concentrations in the nicotine-treated mice, but not in the 
control mice. These findings confirm that the increased DA release present during chronic 
nicotine treatment is mediated by activation of nAChRs.  
 
Evidence for desensitization of nAChRs mediating accumbal DA release has been found 
in rats during continuous nicotine infusion (Benwell et al. 1995). Further, nicotine 
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concentrations similar to those found in the nicotine-treated mice of this study have been 
shown to induce desensitization of nAChRs mediating DA release in in vitro studies 
(Grady et al. 1994; Pidoplichko et al. 1997; Rowell and Hillebrand 1994). However, the 
present findings indicate that, even in the continuous presence of these high levels of 
nicotine, the nAChRs mediating DA release in vivo are not completely inactivated. On the 
other hand, it is to be noted that no enhancement of motor activity and dopamine 
metabolism (Pietilä et al. 1995) were observed in the nicotine-treated mice at 11 h after 
the light offset, when the plasma and brain nicotine concentrations were at their highest. 
Thus, it is possible that at this time point the nAChRs are less sensitive to nicotine. It is 
also possible that the daily fluctuations in nicotine concentrations driven by the oral 
nicotine intake allow resensitization of nAChRs and, thus, DA release in response to 
nicotine could take place repeatedly also during chronic nicotine exposure. This 
suggestion fits well with smokers’ reports that the first cigarette of the day is the most 
pleasurable one (Russell 1989), which could be possible if in the morning, nicotine-
induced activation of recovered nAChRs leads to a greater DA release than occurs later in 
the day.  
 
It has been shown that nAChRs containing the α3 subunit are not as easily desensitized as 
the most common nAChR subtype in the brain, containing α4/β2 subunits (Hsu et al. 
1996; Olale et al. 1997). This suggests that DA release during chronic nicotine 
administration might be mediated by an nAChR subpopulation that is resistant to 
desensitization. Mecamylamine blocks most nAChR subtypes (Decker et al. 1995), so 
more selective nAChR antagonists should be used to clarify which nAChR subtypes are 
most important in mediating increased DA release during chronic nicotine treatment. 
However, it seems reasonable to suggest that desensitization of nAChRs mediating DA 
release is not complete even in a chronic smoker. The powerful reinforcing properties of 
psychostimulant drugs such as cocaine and amphetamine are thought to be related to their 
ability to elicit a sustained increase in extracellular DA release in the nucleus accumbens 
(Balfour et al. 2000; Berridge and Robinson 1998). Thus, if the neurobiological 
mechanisms underlying nicotine dependence are similar to those of other psychostimulant 
drugs, resistance to desensitization of nAChRs mediating release of DA in the mesolimbic 
system of smokers might contribute to sustainment of the smoking habit. 
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6.3. Hypothalamic and cortical noradrenaline and 5-hydroxytryptamine 
 
Acute and repeated nicotine treatments are known to increase the release, metabolism and 
turnover of NA in several brain areas (Benwell and Balfour 1997; Bhagat 1970; Sharp 
and Matta 1993). Thus, the concentration of MOPEG in brain tissue is clearly increased 
by acute nicotine administration (Tani et al. 1997). It seems that tolerance to this effect 
developed in the NMRI mice during the chronic treatment in this study, because no 
increase in MOPEG concentrations were observed in the forenoon, the time point at 
which the striatal DA metabolism was clearly increased. These data suggest that, during 
continuous nicotine treatment, tolerance to the effects of nicotine on cerebral NA 
metabolism is more easily developed than tolerance to the effects on DA metabolism. 
Thus, the effects of nicotine on these two neurotransmitters may be mediated by different 
nAChR subtypes. In the CBA mice, the hypothalamic concentrations of NA and MOPEG 
were significantly increased both at 4 h after the light onset and at 8 h after the light 
offset, whereas the striatal DA metabolism was increased only at 8 h after the light offset. 
It is known that mouse strains differ both in their sensitivity to nicotine and in the 
development of tolerance to nicotine (Collins et al. 1988a). Thus, these different effects of 
nicotine found in CBA and NMRI mice could be due to differences between the mouse 
strains in their responses to nicotine, or alternatively in the daily pattern of fluid and 
therefore nicotine intake. However, the clear increase of NA concentrations observed 
during the chronic nicotine treatment in both mouse strains suggest increased synthesis of 
NA, which is in line with previous studies in rats (Mitchell et al. 1990; Smith et al. 1991).  
 
The concentrations of 5-HIAA were increased on the 50th day of nicotine administration 
in several brain areas, which indicates increased 5-HT metabolism. Water deprivation in 
rats has been found to increase the hypothalamic 5-HIAA levels and decrease the 5-HT 
levels (Popova et al. 2001). Therefore, it cannot be excluded that a state of water 
deprivation due to the reduced fluid intake of the nicotine-treated mice contributed to the 
increase in hypothalamic 5-HIAA concentrations. However, the effects of the long-term 
nicotine treatment on brain NA and 5-HT systems observed in the present study suggest 
that alterations in brain NA and 5-HT neurotransmission may occur in chronic smokers 
and such changes might be involved in the anxiolytic and antidepressant effects of 
 67
nicotine, as well as in increased anxiety and food intake during tobacco withdrawal, and 
thus contribute to the development and maintenance of nicotine dependence. 
 
6.4. Circadian rhythms of brain monoamines 
 
It is possible that the variation in the effects of continuous nicotine treatment on motor 
activity during the day is dependent on circadian variations in the activity of the 
monoaminergic systems in the brain (Hutson et al. 1984; O'Neill and Fillenz 1985; 
Scheving et al. 1968). In previous studies the daily rhythm of striatal DA seemed to be 
altered in NMRI mice during chronic nicotine administration via the drinking water 
(Pietilä et al. 1995). Therefore, in this study the daily rhythms of brain monoamines were 
also studied in other brain areas of both NMRI and CBA mice on the 50th day of nicotine 
administration. This present study revealed no large daily fluctuations in either the 
monoamine or metabolite concentrations in either NMRI or CBA control mice. However, 
it should be noted that the sampling was not very frequent, and significant variations may 
have occured between those sampling times. In the CBA mice drinking tap water, a 
significant daily fluctuation was found in the striatal HVA concentration, which was at its 
highest at 2 h after the light offset, the time point when the mice are supposed to be most 
active, and at its lowest at 8 h after the lights offset. In the nicotine-treated mice this daily 
fluctuation was abolished, because the HVA concentration was actually increased over 
that of control mice at 8 h after the light offset. Thus, it seems that the altered circadian 
pattern observed previously in the striatal DA metabolism of the nicotine-treated mice 
was due to nicotine’s enhancing effect on DA release and metabolism only at time points 
when nicotine was consumed in larger amounts, or alternatively, at time points when 
nAChRs were sensitive to nicotine.  
 
Interestingly, in this study the hypothalamic 5-HIAA levels were elevated in nicotine-
treated mice of both strains only in the light period. The circadian variations in different 
aspects of 5-HT transmission have been studied extensively. The 5-HT synthesis and 5-
HT levels were found to be highest during the hours of light and lowest during the hours 
of darkness, whereas the 5-HT utilisation and 5-HIAA levels have been found to be 
highest during the hours of darkness (Martin and Redfern 1997). In this study, the 5-HT 
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and 5-HIAA levels of control mice were fairly constant during the day, which does not 
exclude the possibility of daily variations occurring in 5-HT neuronal activity not detected 
by measuring tissue 5-HT and 5-HIAA levels. Thus, the finding that the hypothalamic 5-
HIAA levels were increased significantly in the nicotine-treated mice only in the light 
period, fits well with previous results indicating that nicotine’s effect on brain 5-HT is 
highly dependent upon the baseline conditions (Seth et al. 2002). 
 
6.5. Withdrawal from chronic nicotine treatment 
 
In the present study no significant differences in locomotor activity were found between 
control mice and mice withdrawn from chronic nicotine treatment. This finding is in 
agreement with that of Welzl et al. (Welzl et al. 1988), which showed no changes in the 
locomotor activity of rats after withdrawal from chronic nicotine treatment via the 
drinking water. In contrast, during withdrawal from 7-day continuous nicotine infusion 
(3-4 mg/kg day), a significant reduction in the locomotor activity to below that of the 
control animals has been observed for rats (Hildebrand et al. 1997; Malin et al. 1992). 
There are very few reports on nicotine withdrawal in mice. However, in one study 
withdrawal from 14-day treatment with nicotine (0.1 mg/kg twice daily i.p.) induced an 
aversive response in the light/dark exploration test (Costall et al. 1989). More recently, a 
somatic withdrawal syndrome including reduced locomotor activity was demonstrated 
following a 14-day chronic intermittent nicotine treatment with large nicotine doses (2 
mg/kg s.c. four times daily) (Isola et al. 1999). In the present study the effects of chronic 
nicotine treatment on the striatal and cortical monoamines disappeared during withdrawal, 
whereas the hypothalamic NA, MOPEG and 5-HIAA levels were increased 12-14 h after 
withdrawal. However, the concentrations of NA and 5-HIAA were also increased during 
the chronic treatment, which suggests that the changes seen at 12-14 h after withdrawal 
were not necessarily induced by the nicotine withdrawal, but were prolonged effects 
remaining from that induced during the chronic nicotine treatment. Alternatively, the 
changes found in hypothalamic NA, MOPEG and 5-HIAA levels are signs of increased 
stress or anxiety due to the nicotine withdrawal. Although non-specific, some behavioural 
changes such as teeth-chattering, gasps and ptosis exhibited in rats withdrawn from 
chronic nicotine have been shown to resemble the physical signs of opiate withdrawal 
 69
(Malin et al. 1992). It is well documented that morphine withdrawal behaviour is 
associated with elevated brain levels of MOPEG (Maldonado 1997; Swann et al. 1982). In 
the present study, the locomotor activity of the mice was slightly, but not significantly, 
decreased at 12-14 h after withdrawal, as compared with the control mice, suggesting that 
their behaviour was disturbed. However, when the behaviour of the mice was studied on 
the elevated plus-maze at 12-14 or 23-25 h after withdrawal, no anxiogenic response was 
observed (Gäddnäs et al., unpublished data). Thus, spontaneous withdrawal from chronic 
oral nicotine treatment does not seem to induce severe changes in the brain monoamines 
or behaviour of mice.  
 
6.6. Pineal melatonin  
 
Small reductions in the nocturnal pineal melatonin concentration in the mice drinking 
nicotine solution were found in both the ascending and descending phases of the nocturnal 
peak. However, the timing of the melatonin peak was not altered. Although there are no 
earlier published reports on the effects of acute or chronic systemic nicotine treatment on 
the pineal melatonin rhythm in mice, in rats acute nicotine (1-3 mg/kg) was shown to alter 
the timing of the onset of melatonin excretion (Ferguson et al. 1999). That study was 
performed in constant dark conditions though, which makes it less relevant to the present 
study. Because the rhythmicity of pineal melatonin content was not altered in the 
nicotine-treated mice of this study, it is reasonable to conclude that the circadian clock 
function was not affected by the nicotine treatment. This suggestion is also supported by 
the lack of effect of chronic nicotine on the circadian rhythm of motor activity. Thus 
chronic nicotine treatment does not seem to affect circadian rhythms in mice maintained 
on a light-dark cycle.  
 
Regarding the effects of nicotine on the pineal melatonin content, the results are in line 
with results from in vitro experiments showing suppressing effects of nicotine and 
acetylcholine on the NA-stimulated melatonin production through activation of nAChRs 
in the pinealocytes (Stankov et al. 1993; Yamada et al. 1998). The present results are the 
first in vivo demonstration of a nicotine-induced decrease of nocturnal pineal melatonin 
content. Several mechanisms exist whereby nicotine may affect pineal melatonin 
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production. In addition to possible direct effects in the pineal gland, the effects of chronic 
nicotine on pineal melatonin could be mediated via its effects on brain neurotransmitter 
systems. Interestingly, one study showed that a 4-week chronic nicotine administration to 
rats induced down-regulation of cortical β-adrenoceptors. Changes in the pineal β-
adrenoceptors were not measured in that study though (Yamanaka et al. 1987). However, 
the effects of chronic nicotine on pineal melatonin content could possibly be mediated via 
a decreased response of pineal β-adrenoceptors to the nocturnal increase in NA release 
from sympathetic terminals. Also, it should be noted that the reduction in pineal 
melatonin content induced by chronic nicotine treatment could be due to increased release 
of melatonin from the pineal gland. Conclusions regarding the mechanisms mediating the 
decrease in nocturnal pineal melatonin in nicotine-treated mice cannot be drawn based on 
the results in this study, but they suggest that nAChRs may play a role in the regulation of 
pineal function.  
 
 
7. SUMMARY AND CONCLUSIONS 
 
Motor activity and striatal and accumbal DA release and metabolism were all increased in 
parallel in NMRI mice during chronic nicotine treatment. The enhancing effect of the 
nicotine treatment on accumbal DA release was antagonised by the nAChR antagonist 
mecamylamine. Thus, nicotine, delivered chronically to mice in a way that mimics the 
plasma nicotine pharmacokinetics of human smokers, continues to activate nAChRs 
regulating accumbal DA release. Hence, the cerebral DA systems seem to be important in 
mediation of the nicotine-induced locomotor hyperactivity in mice, even after prolonged 
nicotine administration. Resistance to desensitization of the nAChRs mediating release of 
DA in the mesolimbic system of smokers might contribute to their difficulties in breaking 
the habit. 
 
The metabolism of NA and 5-HT in different brain areas were also affected by the chronic 
nicotine treatment, indicating that prolonged nicotine treatment causes changes in all three 
major transmitter monoamines. The hypothalamic NA and 5-HT metabolism were slightly 
increased during nicotine withdrawal. These changes might be related to stress and/or 
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anxiety. However, nicotine withdrawal did not significantly affect locomotor activity, or 
striatal or cortical monoamines, indicating a lack of major behavioural or neurochemical 
changes during withdrawal from a 7-week nicotine treatment via the drinking water. 
 
The present study showed suppressing effects of chronic nicotine treatment on the 
nocturnal pineal melatonin content in CBA mice, suggesting that nAChRs are involved in 
the regulation of pineal function. However, the nicotine treatment did not affect the 
circadian pattern of either pineal melatonin levels or motor activity. Thus, chronic 
nicotine treatment does not alter circadian rhythms in mice maintained on a light-dark 
cycle. 
 
Some differences between mice of NMRI and CBA strains were observed in this study. 
The effects of nicotine on the DA system were more prominent in the NMRI mice than in 
the CBA mice, whereas the most significant effects in the CBA mice were seen on the NA 
system. Different effects of chronic oral nicotine treatment on motor activity and brain 
monoamines were observed at different time points of the day. Thus, the choice of animal 
strain as well as timing of measurements are important factors when clarifying the effects 
of nicotine treatment. 
 
Taken together, the mouse model of long-term nicotine treatment used in this study 
mimics the nicotine intake of chronic smokers well. The amounts of nicotine consumed 
by the mice via the drinking water during their active periods were sufficient to stimulate 
motor activity and striatal and accumbal DA release and metabolism, as measured on the 
50th day of nicotine administration. These findings support the view that limbic and 
striatal DA are critical for the stimulatory effects, and thus, most probably also for the 
reinforcing properties of nicotine. Further, the two other major cerebral monoamine 
transmitters, 5-HT and NA, also play a role in nicotine’s psychopharmacological effects, 
since they showed a response to the chronic nicotine treatment. 
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